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ABSTRACT 
 
The objectives of the study were to (i) identify demographic and clinical 
characteristics of a cohort of psychiatric inpatients who were prescribed 
antipsychotic agents in Armadale Kelmscott Memorial Hospital (ii) evaluate the use 
of antipsychotics and other medications in treating these hospitalized psychiatric 
patients (iii) identify factors influencing prescribing patterns including patient-
related characteristics such as age, gender and nature of condition(s) as well as the 
impact of different psychiatrist teams (iv) calculate the total cost of antipsychotics 
and other medications used in treating these patients and (v) calculate the total cost 
of hospitalization for this cohort of patients. 
 
The medical records of hospitalized psychiatric patients who were treated with 
regular antipsychotic medications in 2005 were reviewed retrospectively. Data 
relating to patients’ age, gender, principle diagnosis, medication details including 
drug name, frequency, route and number of dose administered, and length of 
therapy; laboratory tests related to monitoring of therapy and the treating psychiatrist 
teams were obtained from these records. The data were analyzed to determine the 
association between these demographic and clinical features, and also the patterns of 
clinical use of antipsychotic medications using the chi-squared test. Multinomial 
logistic regression analysis was also conducted to identify factors affecting the 
prescribing of different antipsychotics to admitted psychiatric patients. Data on the 
unit costs of medications, laboratory tests and bed days were collected for 
calculating the costs of antipsychotic, psychotropic, and all drug use; and the total 
costs. A one-way analysis of variance with post-hoc comparison was performed to 
determine whether age, length of stay, diagnosis and pattern of antipsychotic use 
influenced the costs of antipsychotic, psychotropic, and all drug use; and the total 
costs. In addition, the influence of gender and psychiatrist team toward these costs 
was analyzed with independent-samples t-test.  
 
In this study the number of male patients was higher than the number of females and 
their mean age of all patients was 35.87±11.11 years. Almost half of the patients 
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were admitted to hospital for less than 10 days with the mean length of stay of 18.0 
± 18.3 days. The most common diagnosis was schizophrenia, followed by affective 
disorder (bipolar disorder and depression), drug induced psychosis and personality 
disorder. Patients treated by psychiatrist team A were hospitalized longer than those 
by team B and team A treated more schizophrenic patients than team B.  
 
In terms of the use of antipsychotic medications, atypicals were prescribed more 
than ten times as often as typical drugs and around 30% of cases were on 
combination atypicals. Olanzepine, risperidone and quetiapine were the most 
frequent atypicals used. Other psychotropic drugs utilized in this study were 
benzodiazepines, mood stabilizers, antidepressants and anticholinergics. 
Antipsychotic, anxiolytic and hypnotic, and anticholinergic drugs sometimes were 
given as needed drugs. 
 
Only diagnosis influenced the prescribing patters of antipsychotics. Patients with 
schizophrenia were treated relatively more commonly with risperidone and 
combination atypicals than patients with affective disorder and miscellaneous 
disorders. Meanwhile these latter disorders were treated relatively more frequently 
with olanzepine and quetiapine. 
 
The highest total costs of antipsychotic, other drugs, and hospitalization were used 
by patients who were male, aged 35 to 44 years, had lengths of stay of more than 10 
days, and had a schizophrenia diagnosis. Costs were also the highest in patients who 
were treated by psychiatrist team A and on combination atypicals. 
 
The findings of this thesis in relation to the prescribing patterns of 
antipsychotic and other medications to psychiatric patients, the corresponding costs, 
and factors influencing prescribing patterns enables a better understanding to be 
gained of the profile of admitted psychiatric patients and their treatment. In a 
hospital environment with limited budgets, this information is useful for both 
psychiatrists and pharmacists in the future management of patients and in decisions 
relating to the allocation of the pharmacy budget. 
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1 Introduction 
 
1.1 Background 
 
Antipsychotic medications are frequently used by psychiatrists to treat psychotic 
illness and other psychiatric conditions, such as schizophrenia, manic phase of 
bipolar disorder, brief reactive psychoses, psychotic disorders due to a general 
medical condition, depression with psychotic symptoms, psychoses secondary to 
substance abuse (drug induced psychoses), mental retardation, and borderline 
personality disorders. 
1, 2
 
 
Antipsychotic medications are classified into two groups: the first generation that are 
called typical or conventional antipsychotics and the second generation that are 
called atypical antipsychotic agents.
3-5
 Typical antipsychotics have a propensity to 
produce extrapyramidal side effects (EPSE) such as parkinsonism, dystonia and 
akathisia, and the longer term problem of tardive dyskinesia (TD).
2, 4, 5
 Other side 
effects are associated with a reflection of receptor binding agents with potent H1 
blockade that tend to be sedating, while those with peripheral anticholinergic 
(muscarinic) effects have a propensity to cause a dry mouth, constipation, urinary 
retention, and blurring vision, and those with alpha-adrenergic blockade can cause 
problematic postural hypotension. Other potential effects include weight gain, 
hyperprolactinemia, and lowering of the seizure threshold.
2, 4
 Most atypicals are 
associated with substantial weight gain. 
1, 2, 6
 The use of these drugs is also associated 
with the onset or worsening of diabetes mellitus and hyperlipidemia resulting in 
increased risk of heart disease. 
1, 2, 6
 
 
The total use of antipsychotics has increased year by year, with the use of typicals 
decreasing and the use of atypicals increasing dramatically. 
1, 7-9
 Atypicals are being 
used in place of typicals because they can relieve negative symptoms and cognitive 
dysfunction in addition to controlling the positive symptoms of schizophrenia and 
they also cause less severe side effects, especially extrapyramidal side effects. 
1-3, 10
 
Monotherapy upon discharge of atypical antipsychotics was found to be prescribed 
more frequently than typicals. In addition, there has been an increasing trend to use 
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combination typical and atypical antipsychotics and higher doses. 
1, 2, 11-13
  The 
Australian National Guidelines for treatment of first psychosis patients advocate the 
first-line use of atypical agents, and this practice is now commonplace.
14
  
 
Patient demographics (gender, age and ethnicity), onset of illness, duration of illness, 
diagnosis of type and subtype of disorders, number of prior hospitalizations and 
culture affect antipsychotic efficacy for psychiatric disorders. 
11, 15-17
 These factors 
also influence the choice of medications and their dose.
11, 15, 18
 However, the results 
of studies are inconsistent.
15-19
 Several factors such as different diagnostic systems, 
heterogeneity of diagnoses, differences in sample selections, different length of 
follow-up periods, and failure to control for confounding factors may explain these 
inconsistencies. 
15, 16
 
 
Psychiatric illness has a large economic impact not only to the patients but also their 
families, caregivers, the health care system and society.
2, 20, 21
 The greatest 
contributor of the cost of treatment and support of patients is hospitalization and 
medications have a major impact on this cost.
2, 10, 21, 22
 
 
There is still limited evidence relating to the efficacy, tolerability, prevention of 
relapses, and pharmacoeconomic aspects relating to typical and atypical 
antipsychotics, although the second generation medications are far more expensive 
than the first.
1, 23
 While the results of several studies have suggested atypicals are 
more effective and cost effective than typicals, 
1, 7, 10, 17, 18, 24, 25
 Rosenheck has argued 
that the results of several of these studies were questionable.
6
 Reasons for this 
included the increase of drug manufacturer funded clinical trials, flawed study 
designs and misinterpretations of the research results. 
 
Only a few studies have examined the use and cost of antipsychotics in Australia, 
and very few studies have examined factors affecting the choice of the medications 
and their doses. This study will take a cohort of psychiatric patients, those admitted 
to the Armadale Kelmscott Memorial Hospital in 2005, and analyze their use of 
antipsychotics and other medications, calculate the cost of treatment, and identify 
factors influencing the selection of antipsychotic medications. 
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1.2 Objectives 
 
The objectives of the study were as follows - 
1. Identify demographic and clinical characteristics of a cohort of psychiatric 
inpatients who are prescribed antipsychotic agents in Armadale Kelmscott 
Memorial Hospital. 
2. Evaluate the use of antipsychotics and other medications in treating these 
hospitalized psychiatric patients at the Armadale Kelmscott Memorial 
Hospital. 
3. Identify factors influencing prescribing patterns including patient-related 
characteristics such as age, gender and nature of condition(s) as well as the 
impact of different psychiatrist teams.  
4. Calculate the total cost of antipsychotics and other medications used in 
treating these patients. 
5. Calculate the total cost of hospitalization for this cohort of patients. 
 
1.3 Significance 
 
Prescribing patterns of antipsychotics have changed over time. This has cost 
implications for hospital budgets because the second generation treatments that are 
being used more widely are significantly more expensive than the first generation 
treatments, and there is a considerable difference in cost among the different second 
generation antipsychotic drugs. This study will provide information relating to the 
prescribing of antipsychotic medications and other medications to psychiatric 
patients so that a better understanding of prescribing patterns and their cost 
implication can be obtained. It will also provide information to identify factors 
influencing prescribing patterns. These factors may include patient-related 
characteristics such as age, gender and type of condition(s) as well as the impact of 
different psychiatrist team. The results of the study will be useful for both 
psychiatrists and pharmacists to use in the future management of patients. If 
differences are found between the prescribing behaviour of different psychiatrist 
teams, future research could investigate reasons underlying these difference
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2 Literature Review 
 
Then focus of the review of the literature is on psychiatric illness and its treatment. 
The chapter is structured as follows. Sections 2.1 and 2.2. present a background to 
psychiatric disorders and psychotropic medications respectively. Section 2.3 
continues with a discussion of the use of antipsychotic medication including trends in 
its use. In Section 2.4, factors influencing prescribing decisions are covered, and in 
Section 2.5 the costs of treating psychiatric disorders is examined. Section 2.6 
concludes with a discussion of the rationale for the present study, which examines 
the use of psychotropic medicines at a metropolitan hospital in Perth, Western 
Australia.  
 
2.1 Psychiatric illnesses 
 
Psychiatry is a branch of medical science that involves the diagnosis, treatment and 
prevention of mental illness and behavioral disorder such as depression, bipolar 
disorder, schizophrenia, anxiety disorders, personality disorders and the like.
26, 27
 
   
Psychiatric or mental illness is any disturbance of emotional equilibrium, as 
manifested in maladaptive behavior and impaired functioning, caused by genetic, 
physical, chemical, biological, psychological, or social and cultural factors. It is also 
called emotional illness or mental disorder.
2, 26
 
 
Most psychiatric illnesses cannot be cured. Some illnesses have short time courses 
with minor symptoms while other kinds of these diseases have chronic conditions 
and have a significant impact on patients’ quality of life and life expectancy, and 
require long-term or life-long treatment. Efficacy of treatment for any given 
condition is also variable from patient to patient, and can result in complete 
resolution of symptoms or a poor or minimal response.
27, 28
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2.1.1 Schizophrenia and schizophrenia-like disorders 
 
Schizophrenic disorders are one of a large group of psychotic disorders characterized 
by a distortion of reality, disturbances of language and communication, withdrawal 
from social interaction, and disorganization and fragmentation of thought, 
perception, and emotional reaction.
2, 21, 26, 29, 30
 It may express behavior that is 
contrary to the original personality of the patient.
21, 26, 29
 Most patients have both 
positive and negative psychotic symptoms. Positive symptoms include 
hallucinations, delusions and thought disorder; negative symptoms include anergia, 
flatness, and ahedonia.
5, 21, 26, 29, 30
 
 
The condition may be mild or require prolonged hospitalization. No single cause of 
the disorder is known. Genetic, biochemical, psychological, interpersonal, and 
sociocultural factors are usually involved. Although slowly progressive deterioration 
of the personality may occur, dementia is not an inevitable consequence of the 
disorders. There may be recovery in some cases, and there may be relapse marked by 
intermittent episodes that begin after prolonged remission.
2, 3, 21, 26, 30
  
 
Psychiatric disorders that are included in this category are schizophrenia, schizotypal 
disorder, persistent delusional disorders, acute and transient psychotic disorders, 
induced delusional disorder, and schizoaffective disorders.
31, 32
  
 
The annual incidence of schizophrenia is between 0.1 and 0.5 per 1000 of the 
population with the point prevalence around 2.5 to 5.3 per 1000. Although the 
prevalence of schizophrenia is equal in men and women, women tend to have a later 
age of onset than men, and more benign course of illness, including fewer hospital 
admissions and better social functioning. The age of onset is between the age of 16 
and 30 years. The peak onset for men is 15 to 25 years of age and 24 to 35 years for 
women.
2, 21, 29, 30, 32-34
 
 
Antipsychotic medication is the mainstay of treatment for schizophrenia and for 
preventing relapses.
2, 21, 30
 Antidepressant, mood stabilizers (e.g. lithium, valproic 
acid, carbamazepine), and benzodiazepines are commonly used for treating this 
disorder.
21
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2.1.2 Affective disorders 
 
Affective disorders or mood disorders are a variety of conditions characterized by a 
disturbance in mood or affect as the main feature.
26, 29, 31, 35, 36
  The central features of 
these syndromes are, on the one hand, depressed mood, pessimistic thinking, lack of 
enjoyment, reduced energy, and slowness and, on the other hand, elevated mood, 
over-activity, and self-important ideas. The former is called depressive disorder; the 
latter is called mania (or, if it is not severe, hypomania).
2, 29
 The mood change is 
usually accompanied by a change in overall level of activity. Most of these disorders 
tend to be recurrent and the onset of individual episodes can often be related to 
stressful events or situation.
26, 31, 35
 Psychotic symptoms, hallucinations and/or 
delusions related with a worse prognosis occur in both depression and mania.
35, 36
 
 
Affective disorders comprise a group of related psychiatric and medical disorders, 
which include bipolar disorder, unipolar disorder, general anxiety disorder, manic 
episode, depressive disorder, cyclothymia and dysthymia.
29, 31, 36, 37
 They are caused 
by an interaction between stressful events and other factors resulting from genetic 
contribution, childhood experience, physical illness, psychological, and biomedical 
disturbances.
2, 29, 36, 37
 
 
The lifetime prevalence of mood disorders has been reported as 2 to 25%.
2, 33, 36
  The 
prevalence of depressive disorder is 10 to 25% for adult women and 5 to 12% for 
men.
33, 36, 38
   In the oldest group (≥ age 65), the prevalence is lower than the younger 
age groups.
32
 The age of onset of major depression is around 27 years of age.
2, 32
   
 
The prevalence of bipolar disorder is the same across sexes but type II (in which 
hypomanic and frequent depressive episodes occur ) is more common in women than 
men.
32, 36, 39
 The onset of this illness is adolescence and young adult, between 15 and 
30 years old.
2, 32, 36, 39
  
 
Management of affective disorder with drugs uses antidepressants, mood stabilizer 
and antipsychotics and often in combination. Lithium salts, carbamazepine, valproic 
acid formation and lamotrigine prevent recurrence of bipolar disorder.  
  8 
Antipsychotics (e.g. risperidone, olanzapine, quetiapine) are for treating psychotic 
symptoms of affective disorders.
2, 36, 40, 41
 
 
2.1.3 Drug- or substance-induced psychosis 
 
In the tenth revision of the International Classification of Diseases and Related 
Health Problems-Australia Modification (ICD-10-AM), drug induced psychosis is 
included in mental and behavioral disorders due to psychoactive substance use 
category.
31, 42
 It is a group of psychotic symptoms that occur during or following a 
long term-basis of alcohol or psychoactive substance use that may or may not have 
been medically prescribed.
27, 31-33, 42, 43
 Substance intoxication or substance 
withdrawal with more severe symptoms than their common symptoms are included 
in this diagnosis.
31, 33, 42
  
 
Substance use disorders are extremely common and frequently comorbid with other 
mental disorders. 
38, 42
 Beside psychosis, psychiatric disorders that frequently occur 
among patients with drug use problem are depression, anxiety disorders (particularly 
social phobias), and personality disorders.
3
 In addition, many psychiatric patients 
also use drugs such as alcohol, cannabis, and amphetamines.
3, 21, 33, 38, 44
 Alcohol and 
drug abuse may mimic a wide range of mental disorders and lead to misdiagnosis or 
misguided treatment.
38, 42
  Treating both substance use disorders and comorbid 
mental disorders is essential to getting good outcomes.
38
 
44
 
 
Abuse and dependence on substances are more common in men than in women, with 
the difference more marked for non-alcohol substances than for alcohol.
32, 33, 44
 The 
highest prevalence rate of substance abuse is in the 18 to 24 year age group.
33
    
 
Identifying the substances involved is crucial in treatment of this illness, Therapy 
with antipsychotic drugs such as olanzapine and haloperidol for immediate and 
short–term control of psychotic or aggressive behavior may be needed. For 
controlling agitation and anxiety, benzodiazepines may also be useful.
33, 43, 44
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2.1.4 Personality disorders 
 
The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-
IV) defines a personality disorder as “an enduring pattern of inner experience and 
behaviour that deviates markedly from the expectations of the individual’s culture, is 
pervasive and inflexible, has an onset in adolescence and early adulthood, is stable 
over time, and leads to distress or impairment” (p. 629).32   
 
People suffering these disorders usually refuse psychiatrist help and recovery is 
difficult because they do not recognize their symptoms. They often have problems in 
work and in social behavior. 
33, 35
 
 
These disorders have an onset in childhood, adolescence or early adulthood and are 
relatively chronic and stable throughout adult life.
32, 33, 35
  Of the general population, 
around 10 to 15% would be diagnosed with a personality disorder. 
35
 The prevalence 
of personality disorders within clinical settings is about 50% and 60%.
32
  
 
In DSM-IV these disorders are classified into three groups. Cluster A consists of 
paranoid, schizoid, and schizotypal personality disorders. This group is more 
commonly suffered by people who have biological relatives who are schizophrenic 
and seem odd and eccentric.
33, 35
 Paranoid personality disorder is more common in 
males than in female.
32
 Cluster B involves antisocial, borderline, histrionic, and 
narcissistic personality disorders, with borderline personality disorders being the 
most prevalent within hospital clinical settings. People with these disorders seem 
dramatic, emotional and erratic. Approximately 15% of all psychiatric inpatients 
(51% of inpatients with a personality disorder) and 8% of all psychiatric outpatients 
(27% of outpatients with a personality disorder) have a borderline personality 
disorder. Approximately 75% of persons with this disorder will be female.
32
 The 
disorder is often diagnosed in children and adolescents. Anti social personality 
disorder is much more common in males than in females. Cluster C covers avoidant, 
dependent and obsessive-compulsive personality disorders. People with these 
disorders often seem anxious or fearful. Both cluster B and C apparently have a 
genetic base.
33, 35
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Antipsychotic medications (olanzapine, risperidone, haloperidol), antidepressants 
(tricyclic antidepressants, selective serotonin re-uptake inhibitors) and mood 
stabilizer may be used for the treatment of personality disorders, especially for 
borderline personality disorder.
35
 
 
2.1.5 Other psychiatric disorders 
 
In this study all psychiatric disorders other than the four diagnoses previously 
mentioned were classified in the “miscellaneous” category. Disorders included in this 
category are organic (including symptomatic) mental disorders, which have an 
etiology in cerebral disease, brain injury, or other insult leading to cerebral 
dysfunction; neurotic, stress-related and somatoform disorders; behavioral 
syndromes associated with physiological disturbances and physical factors; and 
disorders of psychological development.
31
 
 
2.2 Psychotropic medications 
 
Psychotropic medications are drugs that affect the mind, emotions and behavior.
26
 
These drugs act directly or indirectly on the central nervous system to affect mental 
and emotional processes. Psychoactive and psychopharmacology are alternative 
terms.
37, 45
 
 
Psychotropic medications are used to treat mental illness. They are mostly synthetic 
compounds, although some are naturally occurring. They sometimes have adverse 
side effects that may reduce patients' drug compliance. Some of these side effects can 
be further treated by using other drugs such as anticholinergic (antimuscarinic) 
medications.
2, 29, 38, 46
 
 
Psychotropic medications are commonly grouped as antipsychotic medications, 
antiparkinsonian or anticholinergic medications, anxiolytic and hypnotic 
medications, mood stabilizers, antidepressants,  and various other types of 
medications, such as those used in the treatment of substance misuse and dementia
3, 
38, 45-47
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2.2.1 Antipsychotic drugs 
 
The term antipsychotic is applied to a group of drugs used to treat psychosis. These 
drugs are the cornerstone of treatment for schizophrenia and other psychotic 
disorders and work to reduce psychotic symptoms and prevent relapses.
2, 5, 21, 38
 They 
are also effective in the treatment of other psychiatric disorders, such as bipolar 
disorder, depression with psychotic features, personality disorders, substance-
induced psychotic disorder.
2, 33, 35, 36, 38, 48
   
 
All antipsychotic drugs tend to block the D2 receptors in the dopamine pathway in 
the brain so the normal effect of dopamine release in the relevant synapses is 
reduced. The range of interactions can produce different adverse effects.
2, 3, 5, 49
 
 
There are currently two main types of antipsychotics in use, the typical 
antipsychotics and atypical antipsychotics.
3, 5
 Both types of antipsychotic drugs are 
efficacious and the differences among them are only in their potency (the dosage 
needed to produce the desired effect) and side effects.
2, 38
 
 
2.2.1.1 Typical antipsychotic medications 
 
The typical antipsychotic drugs are now out of patent so that any pharmaceutical 
company is legally allowed to produce cheap generic versions of these drugs. This 
makes them a great deal cheaper than atypicals, which are still in patent.
3, 5
 
 
Typical antipsychotics are not particularly selective and also block the D2 receptors 
in the mesocortical pathway, tuberoinfundibular pathway and the nigrostriatal 
pathway. Blocking D2 receptors in these pathways is thought to produce some of the 
unwanted side effects (extrapyramidal side-effects) of the typical antipsychotic 
medications.
2, 3, 30, 47, 49
 D2 blockade also leads to increased prolactin levels and 
associated sexual dysfunction.
2, 30
 
 
Among the older antipsychotic drugs, drugs that are the most potent (e.g., 
haloperidol) tend to produce more extrapyramidal side effects, and those that are less 
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potent (e.g., chlorpromazine) produce more sedation, postural hypotension, and 
anticholinergic effects.
5, 38
 
 
Typical drugs include chlorpromazine, pericyazine, thioridazine, droperidol, 
haloperidol, zuclopenthixol and pimozide.
3, 5, 19, 38
 
 
2.2.1.2 Atypical antipsychotic medications 
 
Atypical antipsychotic drugs are preferred as a first line treatment of psychosis due to 
the fact that they are believed to have fewer side effects and seem to have additional 
benefits for the negative symptoms of schizophrenia.
2, 3, 5, 50, 51
 
 
Atypical antipsychotics have a similar blocking effect on D2 receptors but seem to be 
a little more selective than typicals. They act preferentially on mesolimbic rather than 
nigrostrial neurons. They also block or partially block serotonin receptors. This 
combination of effects on both dopamine and serotonin receptors might be the reason 
atypical antipsychotic drugs tend to have fewer extrapyramidal side effects than 
typical medications and have an additional effect on the negative symptoms of 
schizophrenia.
2, 3, 5, 19
 Although they are less likely to cause extra pyramidal side 
effects, these drugs cause weight gain, hypotension, type II diabetes, elevation of 
cholesterol, triglycerides, and glucose serum level.
2, 5, 30, 52
 
 
Amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone and 
ziprasidone are all atypical antipsychotics.
2, 3, 13, 19, 47
 
 
2.2.2 Anti-depressants 
 
The mode of action of antidepressants is determined by receptor-mediated signal 
transduction in serotonergic or noradrenergic pathways. Treatment of major 
depression is the main role of these drugs. They are also indicated for treating other 
psychiatric disorders. These drugs combined  with psychological therapies  are used 
in the treatment of anxiety disorder, panic disorder, obsessive compulsive disorder, 
agoraphobia, social phobia (social anxiety disorder) and bulimia nervosa, in addition 
  13 
to other indications such as chronic pain.
3, 35, 38, 41
 Antidepressants are of use when a 
depressive component of the personality is present.
33, 35, 41
 
 
Onset of the response of all antidepressants usually takes at least 1 to 2 weeks.
3, 47
 It 
is preferable to commence at a low dose, and then increase to the minimal dose likely 
to be effective to see if there is a response, rather than to escalate rapidly and often 
unnecessarily.
3
 Combinations of antidepressants have not been shown to be more 
effective than monotherapy, and there is a significant risk of serious adverse effects. 
In addition, the risk of dying in the event of overdose is increased. 
3
 Individual drugs 
differ in their adverse effect profiles, their potential for drug interactions, and their 
safety. This is critical in selecting which antidepressant to use.
3, 38, 47
 
 
The first line of treatment should be a newer antidepressant including the selective 
serotonin reuptake inhibitors (SSRIs) (e.g. sertraline), mirtazapine, moclobemide, 
reboxetine, and venlavaxine.
3, 36, 38
 Although most of the newer antidepressants may 
initially cause agitation, insomnia, nausea, and headache, and over time, sexual 
dysfunction, among other side effects, they are generally safer and more tolerable to 
patients than the older tricyclic antidepressants (TCAs) such as amitriptyline and 
imipramine; and irreversible nonselective monoamine oxidase inhibitor (MAOIs), 
such as phenelzine and moclobemide. 
3, 38
  
 
SRRIs such as sertraline and fluoxetine are effective for the treatment of major 
depressive disorder (MDD). Mirtazapine is also an efficacious antidepressant with 
faster onset of action than SSRIs based on comparison trials.
38
 Mirtazapine is not 
associated with adverse cardiac effects and has been safe in overdose. It is quite 
sedating and thus generally administered at bedtime. Mirtazapine has been 
successfully combined with SSRIs and venlavaxine for partial responders or 
nonresponders to  the other drugs.
38
 
 
The safety and side effect profile of venlafaxine, a serotonin-norepinephrine reuptake 
inhibitor (SNRIs), is generally similar to that of the SSRIs.  Like other newer agents, 
venlafaxine is safer in overdose than older agents. Venlafaxine represents an 
alternative to tricyclics and is considered to have similar efficacy profile but a more 
favourable acute and long-term side effect burden. Some clinical trial data suggest 
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that the rate of remission with venlafaxine  can be higher than for some of the SSRIs 
for populations with relative more severe and melancholic depression.
38, 41
  
 
The main negative aspects of TCAs use are their anticholinergic, postural 
hypotension, sedating properties and cardiovascular adverse effects in susceptible 
individuals or in overdose.
3, 38, 41
   
 
Second-line therapy with TCAs, mianserin, and MAOIs would in general only be 
used after unsuccessful trials of several first-line antidepressants. It should also be 
noted that some patients, particularly those with severe or melancholic depression, 
only respond to second-line therapy.
3, 41
 
2.2.3 Mood stabilizers 
 
The term mood stabilizer is used widely for drugs used in the treatment of bipolar 
disorder. In general, mood stabilizers are a drug that is effective for the acute 
treatment of mania and/or bipolar depression, a drug that prevents episodes of mania 
and/or bipolar depression and a drug that possesses both of these clinical profiles.
3, 38
  
The drugs that are included in this group are carbamazepine, lamotrigine, lithium and 
sodium valproate.
3, 36, 41
  
 
The best established mood stabilizers are lithium and the anticonvulsant, valproate.
36, 
38
 Lithium has been the mainstay of treatment for bipolar disorder for the past three 
decades but its serum concentration should be carefully monitored as it has a narrow 
therapeutic index.
3, 38
  Many experienced clinicians find that valproate has efficacy 
equivalent to that of lithium but greater acceptability to many patients based on side 
effects and ease to use.
38
. Valproates also are found to be more efficacious than 
lithium among manic patients with mixed symptoms.
39
 Therefore, it also has become 
a first line treatment, although greater overall benefit may still rest with lithium. 
41
 
 
Newer anticonvulsants and the second-generation antipsychotic drugs have also 
shown an effect as mood stabilizers.
38, 41
 Carbamazepine is an effective alternative 
treatment for manic episodes when lithium or valproate is ineffective, 
contraindicated, or not tolerated.
38, 39
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2.2.4 Anxiolytics and hypnotics 
 
 Anxiolytics are drugs used primary to treat episodes of anxiety.
3, 41, 53
 Common 
kinds of anxiolytics include barbiturates, benzodiazepines, zolpidem, zopiclone and 
buspirone.
3, 26, 54
  
 
Benzodiazepines also have antiepileptic, muscle relaxant and memory impairing 
actions. The main disadvantage of benzodiazepines is physical dependence and they 
can impair performance and affect judgment so that driving and other skilled tasks 
can be impaired. These compounds are effective in relieving anxiety symptoms and 
can induce sleep. Problems arising from the use of benzodiazepines include 
overdose, particularly from the use of benzodiazepines together with other sedative 
drugs, and dependence as a result of long-term use.
3, 47
  In acute psychotic episode, 
anxiety, agitation and insomnia can be treated with short term benzodiazepine 
therapy to achieve the appropriate level of sedation.
3, 41, 54
 
 
Buspirone has little sedative effect and its most common adverse effects are 
drowsiness, dizziness, dysphoria, lightheadedness, nausea and headaches. There is no 
cross tolerance between buspirone and benzodiazepines, and buspirone cannot be 
used for benzodiazepine withdrawal.
3
 
 
Zolpidem and zopiclone have similar sedative properties to the benzodiazepines but 
minimal anxiolytic, muscle relaxant and anticonvulsant properties. They are used as 
hypnotics in the short-term management of insomnia. Compared with 
benzodiazepines, they generally cause less morning sedation and do not affect 
normal sleep patterns. They are fewer reports of dependency or illicit use by 
substance abusers. Common adverse effects include diarrhea and dizziness 
(zolpidem) and bitter taste (zopiclone).
3, 47
 
 
Pharmacotherapy is useful in dealing with agitation and anxiety in paranoid 
personality disorder.
54
 In most cases an antianxiety agent such as diazepam is 
sufficient. But it may be necessary to use an antipsychotic, such as thioridazine, or 
haloperidol in small dosages and for brief periods to manage severe agitation or 
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quasi-delusional thinking. The antipsychotic drug pimozide has been successfully 
used to reduce paranoid ideation in some patients.
33, 35, 36
 
 
2.2.5 Anticholinergic drugs 
 
Anticholinergic drugs with central anticholinergic action are used to reduce some 
extrapyramidal effects caused by antipsychotics. Drug-induced parkinsonism, 
dystonia and akinesia respond reasonably well, but tremor respond less and akathisia 
has poor response. Antiparkinsonian drugs include benztropine, benzhexol, biperiden 
and orphenadrine. Benztropine can be sedating.
1, 3, 38, 54
 
Routine administration of anticholinergic drugs with antipsychotics is not generally 
favored except when parenteral administration of high potency typical antipsychotics 
is being undertaken.
3, 38, 54
  The reasons are some patients develop adverse effects to 
the antiparkinsonian drug, not all patients develop extrapyramidal adverse effects to 
antipsychotics and abuse of antipsychotics is frequent.
1, 3, 54
  
 
If a high-potency traditional antipsychotic drug is used, an anticholinergic drug often 
should be added as prophylaxis against dystonia. 
3, 38, 54
 Benztropine may be 
preferred because it lacks the antishitaminic effects and it may be given at a dose of 2 
mg twice a day.
3, 38
 
 
2.2.6 Drugs used in alcohol and drug disorders 
 
Therapy for patients with substance disorders are used in the detoxification and 
management of withdrawal symptoms; and also the treatment for co-occurring 
mental disorders.
38, 43, 55
 
 
Acamprosate and disulfiram are used to reduce relapse after detoxication in patients 
with alcohol dependence. In some people it reduces alcohol craving, some of these 
people remain abstinent, others drink less alcohol.
3, 55
 It is important that 
acamprosate is only used as an adjunct to psychological and social treatments 
because the long-term benefits of acamprosate are unclear. Disulfiram is used in the 
treatment of alcohol dependence in highly motivated, and compliant patient.
3, 38, 55, 56
 
Person undergoing withdrawal or experiencing hallucination or delirium are treated 
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with antipsychotic drugs.
38
 Mild illusion may be treated with benzodiazepines.
43, 55
 
Anticonvulsants such as carbamazepine, valproic acid, and gabapentin have also 
been used in the treatment of alcohol withdrawal. Thiamine deficiency is not 
uncommon in alcoholics experiencing withdrawal symptoms due to their poor 
dietary practices. Patients should receive thiamine, 100 mg daily, at the start of 
treatment.
3, 38, 56
 
 
Buprenorphine is a partial opioid agonist used in the treatment of opioid dependence. 
Compared with methadone it has the advantage of lower overdose risk and less 
physical dependence. It is normally administered sublingually once daily.
3
 The doses 
of buprenorphine and methadone need to be determined individually.
3, 38, 55
 
 
2.2.7 Other drugs used in psychiatric illness 
 
Psychostimulants can produce central nervous system stimulation. They are currently 
approved only for the treatment of attention deficit disorder with hyperactivity 
(ADHD) and for narcolepsy
3, 38
  Their efficacy in ADHD has been demonstrated in 
all age groups, in which it has been shown to reduce hyperactivity. These drugs can 
also be used as antidepressant augmentation for nonresponders and partial 
responders.
38
  The availability of extended-delivery preparations has reduced the risk 
of misuse of stimulants.
3, 38
  Dexamphetamine produces pronounced stimulation of 
the CNS and increase motor activity, mental alertness and wakeness. It can also 
produce euphoria. Methylphenidate and modafinil are also included in this drug 
group.
3
  
 
The most common forms of dementia are Alzheimer’s disease and vascular dementia 
and mixed forms.
38
 Cholinesterase inhibitors such as donepezil, galantamine and 
rivastigmine, are used in the treatment of mild and moderately severe dementia. They 
enhance cholinergic function in the central nervous system through reversible 
inhibition of acetylcholinesterase.
3, 38
 Care should be taken when introducing these 
medications in patients with asthma, chronic obstructive airways disease, cardiac 
conduction abnormalities and peptic ulcers.
3
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Clonidine is used to control autonomic symptoms of opioid withdrawal and is used in 
the treatment of Tourette syndrome.
3, 38
 Propranolol is used to treat the motor effects 
of antipsychotic-induced akathisia and prominent sympathetic symptom of acute 
anxiety disorder and social phobia (social anxiety disorder). It does not directly 
influence the psychic aspects of anxiety.
3
  
 
2.3 The use of antipsychotic medication 
 
Antipsychotic drugs play a central role in the treatment of most mental and 
behavioral disorders that require admission to hospital.
2, 57
 Prescribing of 
antipsychotic drugs have vast diversity in terms of dose, indication, and combination 
with other psychotropic medications.
2, 46
 Although the majority of experts and 
textbooks of psychiatry suggest monotherapy of psychotropics, psychopharmacology 
polypharmacy is considered to be essential in specific cases such as treatment for 
high level of agitation and danger to the patient himself or others and therapy 
resistance.
12, 46, 58
 
 
2.3.1 Antipsychotic medication for treating psychiatric disorders 
 
Antipsychotic medications are the cornerstone of treatment for psychotic illnesses. 
They are effective both for acute exacerbations and for long-term maintenance.
2, 3, 38
  
 
Typical antipsychotics are more effective in treating positive than negative 
symptoms. Side effects of these drugs may mimic both positive and negative features 
of schizophrenia.
3, 5, 38
 Their extrapyramidal side effects may not be differentiated 
with negative symptoms and the feature of akathisia can be similar with agitation and 
anxiety (positive symptoms). 
38
 
 
Standard practice for initial treatment of psychoses is using second generation 
antipsychotics or atypicals, such as risperidone, olanzapine, ziprasidone, aripiprazole, 
and quetiapine of which olanzapine and risperidone are the most frequently used.
2, 13
 
For chronic schizophrenia refractory and refractory atypical psychoses, olanzapine is 
more effective than other antipsychotics.
38
 A benzodiazepine (e.g. lorazepam) is 
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added when agitation cannot be controlled. High potency first-generation 
antipsychotics (e.g., haloperidol) are reserved for nonresponders and partial 
responders with these two medications.
3, 38
  
 
In treating bipolar disorder, antipsychotic drugs are used as mood stabilizers 
although psychosis symptoms are not present and patients have already used a mood 
stabilizer as prophylaxis. Antipsychotics are useful for acute mania, prophylaxis for 
preventing recurrent mania and bipolar depressive symptoms.
2, 13, 38
 
 
The combination of an antipsychotics and antidepressants is more effective in 
treating depression with psychotic features than either class of drug alone. In 
addition, atypicals augment antidepressant drugs in treatment-resistent nonpsychotic 
depression.
38
 Although some clinicians treat the most severe depressed patients with 
the older TCAs, the standard practice for this illness are combinations atypical drugs 
with newer antidepressants (e.g. SSRIs).
38
  
 
The dosage of antipsychotics for depression with psychotic symptoms is usually 
slightly lower than the dosage used in acute psychoses. Patients may use an initial 
dosage that is equivalent to 4 to 6 mg of haloperidol per day or 5 to 10 mg per day 
olanzapine.
38
 
 
Atypical antipsychotics offer some antidepressant effect and they can be used alone 
without antidepressants. In addition, they give less extrapyramidal side effects and 
tardive dyskinesia in which patients with mood disorder are more vulnerable.
38
 
 
In treating patients diagnosed with drug induced psychosis, antipsychotics such as 
olanzapine and haloperidol are used to control psychotic or aggressive behavior with 
benzodiazepines for controlling agitation and anxiety.
33
  
 
The antipsychotic drugs have been used in severe personality disorder (e.g., 
borderline) patients during periods of psychotic thinking and in treating and 
preventing episodes of impulsiveness, rage, and assaultiveness. Atypical 
antipsychotic drugs give more promising results.
35, 38
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2.3.2 Long-acting preparations of antipsychotic medications 
 
The use of long-acting antipsychotic medications should be considered for patients 
who relapse because of noncompliance or the patients are unable to take oral 
medication.
3, 38
  The depot preparations of fluphenezine decanoate, zuclopenthixol 
decanoate, haloperidol decanoate and risperidone decanoat are available in 
Australia.
3, 47
  
 
The following guidelines are recommended when giving long-acting antipsychotics 
to get a safe and effective treatment. Before giving long-acting medication, a small 
dose is usually given orally to check adverse effects. The treatment starts with a low 
dose with oral supplementation to stabilize the treatment. The dose does not increase 
rapidly and to achieve a steady state plasma level may take 3 to 6 months (four to 
five dosing intervals). Symptoms of adverse effects should be monitored carefully to 
ensure the efficacy of treatment.
3, 38, 47
 
 
Compared with oral risperidone, the use of long-acting risperidone reduces peak 
blood level around 30% and the plasma peak-to-trough ratio by 32 to 42%. These 
reductions may underline fewer adverse effects of long-acting risperidone than oral 
preparation. In addition, only 30% of patients who are treated with long-acting 
risperidon discontinued their treatment whereas almost 75% patients on oral 
discontinued their treatment. The reduction of discontinuation of treatment indicates 
that there is an improvement in patient adherence to the therapy. Switching from oral 
to long-acting risperidone produces an improvement in both symptoms and 
movement disorder.
59
 
 
Shajahan et al
60
 conducted a study comparing the effectiveness of long-acting 
risperidone with zuclopenthixol during a three year period (2002-2005). The results 
indicated that discontinuation due to adverse effect was less with risperidone than 
with zuclopenthizol (26% versus 63%, p=0.06). But both therapies are clinically 
effective in the longer treatment of psychotic disorder. 
 
On the other hand, a study by Rubio et al
61
 in chronic schizophrenia patients with 
substance use disorder showed that risperidone was more useful than zuclopenthizol 
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in reducing substance abuse and in alleviating symptoms of schizophrenia. Again the 
compliance of patients with risperidone was better than patients with zuclopenthizol.  
 
   
2.3.3 As needed (pro renata= PRN) use of antipsychotic medications 
 
Antipsychotic drugs given as pro renata use is a common practice in hospital. The 
purpose of administering antipsychotics this way is usually as acute treatment of 
psychotic symptoms or agitation. Giving pro renata antipsychotic drugs may indicate 
absence of a clear diagnosis or treatment strategy. 
38, 62-64
 
 
Patients receiving antipsychotic on an as-required basis are more likely to do poorly 
and they may be more likely to also be using an anti depressant on an as-needed 
basis. Moreover, in cases when patients are receiving only intermittent antipsychotic 
drug doses, physicians may get confused regarding the amount of antipsychotics that 
improves the psychotic disorder. 
38, 62-64
 
 
Using as-needed antipsychotics in longer term should be monitored because it may 
worsen the side effects or undiagnosed medical condition. 
38
 
 
2.3.4 Trends in the use of typical and atypical antipsychotic 
medications 
 
The use of typical antipsychotic drugs has tended to decrease because of the side 
effects that are experienced by patients using this drug. On the other hand, there is an 
increasing trend in the use of atypicals.
5, 8, 9, 57
 
 
The results of several clinical studies have shown that atypical antipsychotics are 
more effective in treating patients who are resistant to typical drugs, can control the 
negative and depressive symptoms of schizophrenia, and are associated with fewer 
extrapyramidal side effects. In addition, the use of atypicals to treat psychiatric 
patient reduces the length of stay in hospital.
1, 2, 5
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According to several studies in different countries, the increasing use of atypical 
antipsychotics has been followed by an increasing use of multiple antipsychotic drug 
regimens despite the lack of clinical and research data encouraging their use. In 
addition, an increased use of multiple antipsychotic drugs has been accompanied 
with increased doses of these drugs and the simultaneous use of other psychotropic 
drugs, such as antidepressants and mood stabilizers.
1, 65
 
 
2.3.5 Monotherapy and polytherapy of antipsychotic  medications 
 
According to the current guidelines for treatment of psychotic disorders, atypical 
antipsychotic medications are first-choice therapy and the recommendation is to 
avoid polytherapy, especially combinations of atypical and typical antipsychotic 
drugs.
1, 58
 
 
The results of surveys in the United States and several European countries revealed 
that psychiatric university clinics have a tendency to apply monotherapy to treat their 
patients with psychiatric illnesses but in psychiatric non-university clinics the use of 
monotherapy has decreased year by year.
46
  
 
Also, in clinical practice, the use of a combination of atypical and typical 
antipsychotics to treat psychiatric patients, particularly in chronically ill psychotic 
patients, seems to be quite frequent and increasing. 
1, 58, 66, 67
  In a study conducted in 
Italy by Mauri et al
1
 there was an increasing trend to use a combination of one 
typical and one atypical antipsychotic drug, and in the study conducted by Centorrino 
et al the combination of one typical and one atypical was the most common 
combination.
66
 This tendency may reflect incomplete confidence in monotherapy 
with atypical antipsychotic agents.
66
 In patients who typically show only limited 
benefits of treatment, the simultaneous use of more than one antipsychotic agent may 
reflect hopes for greater effectiveness of treatment involving drugs with somewhat 
dissimilar actions despite the lack of research evidence of superior effectiveness, a 
compromise of safety or an increase in the cost of care.
1, 66, 67
  
  
Some countries such as Spain, Italy, Ireland, Germany, Denmark, England, Finland, 
Belgium, the Netherland and Norway do not accept drug combinations because 
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besides scant evidence that a combination of drugs is more effective than one-drug 
regimes; there is a greater risk of medication error in patients and also of serious 
cardiovascular and depressive side effects.
57
 
 
There is some evidence that patients are treated with non-psychotropic drugs 
alongside psychotropics, which leads to patients being administered too many drugs. 
Polypharmacy in the treatment of psychiatric disorders is promoted by therapy 
strategies such as giving two drugs with a similar profile for one purpose, treating 
side effect by giving another drug instead of reducing the doses of the first, 
prescribing another different drug rather than increasing the dosage of the same one 
up to maximum, and starting a new treatment without stopping the ineffective one.
46, 
58
 
 
2.4 Factors influencing prescribing decision 
 
There is a significant difference in the pattern of antipsychotic use in different places 
and the pattern is influenced by several factors. These factors are associated with 
both the characteristics of patients and physicians.  
 
Factors that are associated with patient characteristics that have been found to affect 
psychotic treatment are sociodemographic characteristics such as age, sex, race, 
education, family status, employment and income as well as patients comorbidities 
such as the presence of a substance abuse disorder or comorbid depression with 
anxiety. 
57, 68, 69
 Patients’ responses to psychotropic drug, their medical diagnosis, and 
expectations also impact on the prescribing of drug therapy.
57, 69
  
 
Bowers et al. stated that genetic differences in European people could explain some 
differences in prescribing patterns across Europe. Antipsychotic and antidepressant 
are metabolized by a hepatic enzyme CYP2D6 whose activity is determined 
genetically.
57
 
 
Diagnosis undoubtedly plays an essential role in drug therapy decisions and is the 
foundation from which the physician makes an appropriate decision.
69
  Diagnosing 
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of psychiatric illnesses is more complicated than other disorders because mental 
disorders do not generally lend themselves to laboratory tests, physical 
measurements, and other means normally used to assist the physician in disease 
identification.
69
  In addition, diagnosis does not always provide sufficient 
information to determine the appropriate or inappropriate use of psychotropic 
drugs.
69
 Inadequate diagnostic information on medical records is likely to be the 
cause for some of the considerable off-label use and therapy differences.
68
 
 
Some patients demand psychotropic drug therapy because they have become more 
willing to bring stressful life situation to the attention of their physician. 
69, 70
 Also 
more people consult doctors for their ailments and express their desire for drug 
therapy to the physician because health services are more available. 
69, 70
 According 
to this view, doctors are only passive distributors of drugs.
70
  Once a doctor has 
prescribed psychotropic drugs and taught his patients an easy and acceptable way to 
handle their problems, perhaps on subsequent visits the patients may ask for these 
drugs again. Other patients may find out this approach of solving their disorder 
problems from relatives or friends who have same disorders or from other 
information sources such as the internet. 
69, 70
 The physician’s treatment habits 
appear to affect patient expectations. 
69, 70
  The expectation of patients may be created 
by patients or physicians due to their treatment methods or  by both of them.
69
 
However, Hadsall et al
69
 who investigated factors affecting the prescribing of 
psychotropic and non-psychotropic drugs stated that there was a positive relationship 
between the expectations of drug therapy and non-psychotic drug prescribing. It 
reflected that doctors will prescribe drugs if the patients expect that drug therapy. 
This study indicated that the prescribing of psychotic drugs was much less 
predictable than that of non-psychotrop drugs. 
69
  
 
Factors such as physicians’ attitude in prescribing, physicians’ characteristics such as 
age, managed care involvement, being early adopters of new medical innovations, 
education and the experience of physicians also significantly influence prescribing 
patterns.
68, 69
  
 
Prescribing characteristics of doctors are also affected positively by their colleagues 
as well as the closeness of working relationship with other physicians in group 
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practices.
69
  Some doctors considered other physicians as the most important way to 
find out about new prescription drugs.
70
 Doctors who had intensive contacts with a 
large number of their colleagues knew the new drug before their relatively isolated 
colleagues. However, the effect of other factors, such as advertising and education, 
were found to be greater than that of colleagues.
70
  
 
Inexperienced physicians in the treatment of psychiatric problems are believed to 
assume that medication is the only way to treat the disorder and do not realize that 
other forms of treatment may also be effective.
69
 In a study by Hadsall et al
69
, board 
certified physicians tended to prescribe fewer psychotropic drugs for their patients 
than non-board certified physicians.  In this case, among non-board certified 
physicians there was over-diagnosing of psychiatric problems.
69
  
 
Basic therapeutic skills are provided and maintained by education and  its success 
varies between countries and universities. The results of several studies indicated that 
education positively influences the quality of prescribing. Lower prescribing of drugs 
and higher appropriateness of therapy were associated with higher educational 
qualifications, being younger or having fewer years of professional experience but 
having more postgraduate training.
70
  
 
Representatives of the drug industry argue that advertising helps doctor get up to date 
drug information but the contribution of advertising to prescribing is debatable.  The 
purpose of advertising is to affect doctors’ prescribing habits and to make them 
prescribe as many profitable preparations as possible. By communication and 
manipulation of opinions about drug therapy, advertising can create a new need and 
habits of drug consumption.
70
  
 
A tighter control on the sales for special drugs, for example narcotics, has shown that 
drug consumption could be decreased by control measures, at least for short periods. 
The sale of drugs is also reduced after warnings of their side effects by the Adverse 
Drug Reaction Committee. Several studies showed that during the course of the 
studies the drug usage in hospital was notably decreased in some drug groups and the 
prescribing rates were very low. These studies suggested a positive effect of control 
measures if used effectively. 
70
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2.5 The costs of treating psychiatric disorders 
 
Psychiatric disorders have a major impact on the quality of life of patients and their 
families and significant cost implications.
71
   
 
2.5.1 The categories of costs 
 
Costs are divided into direct costs, indirect, and intangible costs.
20, 71-73
  As the costs 
associated directly with a healthcare intervention, direct costs are categorized into 
direct medical and direct non-medical costs. 
72
 Direct medical costs include the costs 
of services and products used in the care of the patient, and may include expenditures 
for hospital stays, physician and other health professional visits, emergency 
department visits/services, home health care visits, laboratory tests, the cost of 
medications, and medical equipment and supplies.
20, 71-76
 On the other hand, direct 
non-medical costs include the costs of non-medical assistance, food, accommodation, 
and transportation because of the illness or health care intervention.
72
   
 
Indirect costs, which are also known as productivity costs, are the costs of lost or 
reduced productivity resulting from morbidity or premature mortality due to a 
medical condition or treatment. Intangible costs are the psychic costs associated with 
illness or treatment, such as anxiety, pain, depression, worry and other distress that 
patients and/or their families suffer. Because indirect and intangible costs are 
difficult or impossible to measure, most economic studies focus on costs from the 
perspective of the healthcare provider only. This mean that only direct medical costs 
are included.
71-73
  
 
2.5.1.1 Cost of medications 
 
The costs of psychotropic medications have a substantial contribution to mental 
health expenditure and vary from country to country.
68, 71
 In developed countries, 
spending on medications accounts for between 1.1%  and 10% of all direct health 
care costs.
10, 71, 76, 77
 The growth rate per year of average annual spending on 
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psychotropic medications is faster than the growth rate for non-psychotropic 
medications.
68
 
 
In 2001 in the United States, antipsychotic medications were the 13
th
-hightest drug 
category ranked by total retail sales.
68
 The wider use and higher acquisition cost of 
atypical antipsychotic agents increases the share of the drug-costs in total costs. 
However, atypical drugs may prove cost effective if their efficacy reduces inpatient 
stays and results in fewer relapses, fewer inpatient admissions, and earlier discharge 
of patients from hospitals, which potentially reduces the total cost.
71
 
 
2.5.1.2 Laboratory test costs 
 
In the treatment of psychiatric patients, some laboratory tests are conducted to 
identify particular substances, monitor drug levels in urine and serum, and ascertain 
the side effect of medications. Significant expenses can be incurred with these tests.
33
 
 
Investigating psychoactive substances is usually performed for patients with a 
current substance abuse disorder, especially alcohol or opioid use.
3
 It is important to 
investigate the use of other substances, such as benzodiazepine, as multiple drug use 
is very common in this situation. Patients with mental disorders, particularly 
depression, psychoses, bipolar disorders, anxiety disorder (particularly social 
phobias), post-traumatic stress disorder (PTSD) and personality disorders, also often 
use substances such as alcohol, cannabis and amphetamines. 
3, 38, 74
  
 
Serum concentrations of drugs and their metabolites are a good indicator of both 
efficacy and toxicity. Therapeutic concentrations of medications, for example sodium 
valproate and carbamazepine, can be used as a general guide to the dosage of these 
drugs in bipolar disorder. Manic relapses in established bipolar disorder are often due 
to poor medication compliance, so serum concentrations should be checked.
3, 38
 
Serum concentration of drugs with a narrow therapeutic index such as lithium, 
should be carefully monitored for preventing the toxicity of the drug.
3
  
 
Several laboratory tests are conducted for detecting the adverse effect of 
medications. The tests are performed prior to commencing the drugs and the tests are 
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usually repeated during the drug treatment and if there are any clinical features 
suggestive of adverse effects. For example, clozapine that is effective in treating 
refractory patients who are unresponsive to other drugs can cause agranulocytosis. 
Therefore, patients on clozapine require a weekly blood test to monitor their blood 
cell count.
3, 6, 28
 Haematological, renal, electrolyte and hepatic functions should be 
assessed prior to commencing sodium valproate and carbamazepine. The 
haematological and hepatic function should be monitored at least each 3 to 6 months 
after treatment has been initiated.
3
 For prevention of the development of neutropenia 
in mianserin use, a full blood count is conducted prior to use and during the 
treatment. Atypical antipsychotic medications influence cholesterol, lipid and 
glucose metabolism therefore fasting blood glucose and serum lipid estimations must 
be measured around the onset of treatment in all cases and annually thereafter to find 
out whether their level in the blood is above normal levels.
3, 30, 52
    
 
2.5.1.3 Hospital inpatient bed day costs 
 
Unit costs per bed day is a measure of hospital costs i.e., excluding drugs and 
diagnostic/laboratory tests and including other costs such as personnel, equipment 
and capital and food costs.
78
 
 
The hospital inpatient bed day costs are the greatest contributor to the direct costs of 
admitted patients, and thus a reduction in hospital use would have an important 
impact on the overall costs of the illness. 
79-81
 The newer antipsychotic drugs have 
been found to reduce the length of hospital stays, the number of physician  visits, and 
the overall cost of patient management.
28
 Also, the longer patients received the 
newer antipsychotic medications, the fewer days they needed to remain 
hospitalized.
28
  
 
2.5.2 Costs of treating mental disorders 
 
Several studies have compared the costs of atypical and typical agents.
10, 82-85
  These 
studies have suggested that atypical agents induce fewer extrapyramidal adverse 
effects than conventional drugs, improve patient compliance, and reduce the number 
of hospital admissions and hospital length of stay. As a consequence, despite the 
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increased acquisition costs, atypical agents appear no more expensive for health care 
system than typical agents.
82-84
   
 
Hudson et al
10
 reviewed the peer-reviewed literature of cost evaluations involving 
subjects with schizophrenia or a primary psychotic disorder that compared costs and 
benefits of the very expensive novel antipsychotics with those of the very 
inexpensive traditional antipsychotic medications. Several studies presented strong 
evidence for a cost advantage with atypical agents, while the others demonstrated a 
cost-neutral effect of the new generation antipsychotics and, in some cases, improved 
quality of life. In addition, 12 studies found that atypicals were equal or superior to 
typicals in terms of effectiveness.
10
   
 
Rothbard et al assessed the utilization and cost of individuals with severe mental 
illness enrolled in Medicaid program in Florida, Oregon and Pennsylvania during 
1997. The results of this study were that patients in the atypical only group had the 
highest cost for antipsychotics ($1798) and all pscyhotropics ($2174), and patients in 
the typical only group had the lowest ($291 and $578, respectively). Patients in the 
typical only group also had the lowest costs of inpatient services ($2140) and both 
pharmacy and psychiatric services ($3463). The group with the highest cost in these 
categories was in persons on combination typical/atypicals ($4200 and $6590, 
respectively).
86
 
 
Rothbard et al also examined the difference in costs of atypical subgroups. Atypical 
combinations had the highest cost of antipsychotics ($2768) and all psychotropic 
($3121), while risperidone had the lowest of those costs ($1249 and $1558, 
respectively) (p<0.001). Surprisingly, patients in the atypical combination group did 
not use inpatient services, and the olanzapine group had the highest hospital inpatient 
costs ($7873). As a result, the combined cost of medications and hospital care of the 
olanzapine group was the highest ($10231) and the atypical combination group was 
the lowest ($3712).
86
 
 
Other studies
87, 88
 comparing the costs of risperidone and olanzapine treatments 
showed similar  results.
86
  In a study conducted in Israel, Rabinowitz and colleagues 
examined differences in the total mental health care costs for one year following 
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initiation of risperidone or olanzapine in individual within an integrated managed 
mental health pilot project. The average daily retail price for risperidone was 
US$6.85 and for olanzapine was US$13.
85, 88
 Johnsrud and colleagues who 
conducted a study to assess differences in the total mental health care costs for 1 year 
following initiation of risperidone or olanzapine in individual within an integrated 
managed mental health pilot project also found that antipsychotic medication costs 
were significantly lower for individuals prescribed risperidone than olanzapine 
($1763 versus $2582; p<0.001).
87
  Individuals prescribed risperidone had lower (but 
not significant) expenditures for inpatient mental health service ($3476 versus 
$3739; p=0.844), for mental health services that included outpatient and inpatient 
services, ($4714 versus 5077; p=0.792), and for total mental health care costs ($7407 
versus $9011; p=0.255).
87
 
 
However, not all studies have found olanzapine to result in lower costs. For example, 
cost data analysed for 48 olanzapine recipients and 43 risperidone recipients who 
completed 28 weeks’ therapy found that although the drug acquisition costs for that 
period were higher in the olanzapine group ($US2278 per patient) than the 
risperidone group ($US2123 per patient), the total direct healthcare costs were lower 
for the olanzapine group than the risperidone group ($US5630 and $US6123 per 
patient, respectively). This represented a cost saving of $US493/patient for every 6 
months that olanzapine was used instead of risperidone. This cost saving was due to 
saving in both out-patient and in-patients costs.
76
  
 
Schizophrenia as the most common psychoses is probably the most expensive 
psychiatric disorder to treat.
76
 Studies in England
75
 and Italy
89
 indicated that  the care 
of patients with schizophrenia costs twice as much as the care of patients with other 
psychiatric disorders. This study also found that the mean costs for male patients 
were almost twice than that of female patients (€772.42 and €441.11 respectively).89  
 
Percudani et al. also found that the cost of care for patients with schizophrenia was 
higher than for other patients with psychiatric illness. Their study identifying service 
utilization and the cost of first-contact patients in a community psychiatric services 
in Italy found that the average monthly costs per patient were €387 for patients with 
schizophrenia, €149 for mood disorders, €138 for neurotic and related disorders, 
  31 
€129 for personality disorders, and €148 for other diagnoses. In-patient care of 
schizophrenia patients accounted for 74% of total costs, while it accounted for 56%, 
25%, 31% and 25%, respectively, for the other groups.
90
 
 
In another comparison of costs for patients with different types of psychiatric illness, 
patients with bipolar disease were found to have relatively high health care costs 
relative to those with depression.
84
 Stensland et al
84
 found that bipolar patients used 
significantly more psychiatric resources per person than patients with depression, and 
had more mean psychiatric hospital days, psychiatric and medical emergency room 
visits, and psychiatric office visits. Mean direct per-patient costs were $10,402 for 
bipolar patients and $7494 for depression patients (p<0.001), with the primary 
differences observed for psychiatric medication ($1641 vs. $507) and psychiatric 
hospitalization ($1187 vs. $241).
84
  
 
2.6 Structure of dissertation 
  
The literature reviewed in this chapter has illustrated many questions about the use of 
antipsychotic medications in the treatment of mental and behavioural disorders 
including the choice of drug regimens, patterns of prescribing, monotherapy versus 
polytherapy, and the cost of treating patients with mental illness. These issues are 
explored in this dissertation for a cohort of psychiatric patients admitted to the 
Armadale Kelmscott Memorial Hospital in 2005 who are prescribed antipsychotic 
agents.  
 
The dissertation is structured as follows. Chapter 3 discusses the methodology for the 
study. Chapter 4 then presents the study results, and in Chapter 5 the findings of the 
study are discussed and interpreted in the context of the literature. Implications for 
future research are also addressed. 
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3 Methodology 
 
The current study comprised two parts. The first part was a retrospective study of 
medical records of hospitalized psychiatric patients to retrieve demographic and 
clinical data. These data were used to identify the relationship between demographic 
and clinical features, evaluate the use of antipsychotic and other drugs, and identify 
factors relating to prescribing patterns of antipsychotic medications. The second part 
was collecting the cost of medications, laboratory tests and hospital inpatient bed day 
costs for conducting an economic analysis of the direct medical costs of treating 
these patients. 
 
3.1 Ethical approval 
 
The study involved the collection and analysis of patients’ medical records. This 
required ethical approvals, which was obtained from both Curtin University of 
Technology Human Research Ethics Committee (HREC) (Appendix 1) and the 
Armadale Kelmscott Memorial Hospital (AKMH) HREC (Appendix 2). Both 
HRECs also provided a waiver of consent from patients for this study. The 
ethical issues arose as a result of the analysis of patient records and resultant issues in 
relation to confidentiality and the publication of data.  
 
A unique non-patient identifiable code was allocated to each record to enable re-
identification of the record if necessary. The key of the code was held at all time by 
the Manager of Pharmacy of AKMH. To ensure patients anonymity in the database, 
patient codes were kept separately during data entry and data analysis. 
 
The data were kept in the School of Pharmacy, Curtin University of Technology 
during the study and will be stored in a locked archive for period of five years from 
the time of study and will be destroyed after that time. Only the investigators of the 
study are able to access the study records. 
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3.2 Study population 
 
To be included in the study, patients were hospitalized at the Leshen Unit (Adult 
Psychiatry In-patient Unit), AKMH in 2005. Patients had to be at least 17 years of 
age and treated regularly with antipsychotic medications.  
 
3.3 Data collection 
 
The first step was to collect data from the medical records and the second step was 
obtaining the cost data.  
 
3.3.1 Collection of the data from the medical records 
 
Patient details obtained from the medical records included the date of birth, sex, date 
of admission, date of discharge, clinical details such as principle diagnosis, 
medications details including drug name, dose, frequency, route and number of dose 
administered, and length of therapy; laboratory tests related to monitoring of therapy 
and the treating psychiatrist team. Besides the data relating to psychotropic drugs 
such as typical and atypical antipsychotics; antidepressants (SSRI, TCA, MAOI), 
mood stabilisers (litium carbonate, carbamazepine, sodium valproate), anxiolytics 
and hypnotics (benzodiazepines, buspiron, zolpidem), anticholinergic drugs, and 
drugs used in alcohol and drug disorders (acamprosate, buprenorphine, methadone), 
non psychotropic medications were also collected. Non-psychotropc drugs that were 
included were anti-lipidemia (simvastatin, atorvastatin), antidiabetics (sulfonylureas, 
thiazolidinediones, metformin etc), antihypertensives (betablokers, ACE inhibitors, 
etc), antiinfectives (penicillins, macrolides, aminoglycosides, etc.), vitamins (single 
and multivitamin) and other drugs used to treat co-morbidities in psychiatric patients. 
These data were entered into Microsoft Excel sheets.  
 
3.3.2 Collection of the cost data 
 
Data on the unit costs of all medications (primary antipsychotic medications, adjunct 
and side-effect medications) was obtained from the Department of Pharmacy at the 
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AKMH. The unit costs of medication was based on the cost to public hospitals in 
Western Australia derived from the State Tender for Drugs, Disinfectants and 
Antiseptics, and Nutritional Products in 2005 (Contract No 5504).
91
 Unit costs for 
laboratory tests were obtained from the Medicare Benefit Schedule, which was 
retrieved from the website of the Department of Health and Ageing.
92
 Bed day costs 
excluding medications and laboratory tests was obtained from the Business Unit at 
the hospital. Inpatient bed day cost for psychiatric patients was AU $350 per day. 
 
3.4 Data analysis 
3.4.1 Data from the medical records 
 
Statistical analysis of the data was performed using SPSS version 14 for Windows.  
 
As continuous variables, age and duration of admission were assessed for normality, 
and natural logarithm transformations were applied for skewed data. In some 
instances where transformations did not achieve normality, non-parametric tests were 
used. Data relating to age and duration of admission were modified by collapsing 
these continuous variables into categorical variables.
93
 
 
For the descriptive analysis, patients’ ages were classified into five groups. These 
groups were less than 25, 25 to 34, 35 to 44, 45 to 54, and more than 54 years. 
Duration of admission (or length of stay) was also classified into five groups, namely 
1 to 5, 6 to 10, 11 to 20, 21 to 40, and more than 40 days. Before doing statistical 
analysis, several categories were merged if the number of cases in each category did 
not meet with the assumptions of the method of analysis.
93, 94
  
 
Diagnoses were coded based on the International Statistical Classification of 
Diseases and Related Health Problems, 10th Revision (ICD-10)
31
 and were classified 
into six main diagnostic categories.  These six main diagnoses were schizophrenia, 
bipolar affective disorders, depression, drug induced psychosis, personality disorders 
and miscellaneous. Diagnoses included in the miscellaneous category were 
psychiatric disorders that are not suitable with the criteria of the above mentioned 
five diagnoses. In the analysis of the patterns of antipsychotic use, this classification 
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was transformed into three categories, namely, schizophrenia, affective disorders 
(including bipolar affective disorder and depression), and miscellaneous (including 
drug induced psychosis, personality disorder and miscellaneous). 
 
The prescribing patterns of antipsychotic medications were classified into three 
categories. These categories were typical, atypical, and combination typical- atypical 
antipsychotic drugs. Patients in the atypical group had at least one atypical 
antipsychotic during admission. Patients who were on at least one typical drug during 
their admission were included in the typical group. In the combination atypical-
typical group, patients were treated with both atypical and typical drugs during their 
admission. If the patients were treated with more than one antipsychotic, these 
medications were not necessarily taken concurrently. 
 
Descriptive statistical analyses were conducted on the data collected in the review of 
medical records. Frequency and percentage of patients according to age, gender, 
duration of admission, diagnosis, number of drugs and patterns of clinical use of 
antipsychotic medication were presented in tables or pie charts. Means, medians and 
standard deviations were also presented in these analyses, and the data were analyzed 
to determine the correlation between these demographic and clinical features, and 
also the patterns of clinical use of antipsychotic medications. Differences were tested 
using the chi-squared test.  
 
Multinomial logistic regression analysis was conducted to identify factors affecting 
the prescribing of different antipsychotics to admitted psychiatric patients. 
Differences were considered statistically significant at p<0.05. Factors to be included 
in the regression included age, gender, duration of admission, diagnosis and the 
psychiatrist team. 
 
3.4.2 Cost data 
 
Total costs were calculated as the sum of medications, laboratory costs and bed day 
costs (excluding the cost of medications and laboratory costs). The cost data were 
used to calculate the costs of treating admitted psychiatric patients.  
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For the descriptive analysis, means were calculated for antipsychotics, psychotropics, 
all drugs, laboratory tests, bed days and total costs by demographic and clinical 
characteristic. These mean costs for patients who had used only atypival drugs 
(olanzapine, quetiapine, risperidone and combination atypical agents) were also 
calculated. Cost data were presented as means and standard deviations (rather than 
medians and interquartile ranges) despite being skewed. This is common practice in 
economic analysis as it allows total costs to be calculated. 
95
 
 
The distribution of the cost data of antipsychotics, psychotropics, all drugs, 
laboratory data, and total costs were assessed for normality. Natural logarithmic 
transformation was performed for normalizing the cost data. A one-way analysis of 
variance with post-hoc comparison was performed to determine which variables 
influenced the antipsychotic, psychotropic and total costs. The result of the post-hoc 
comparison shows where the differences of mean cost lies. Meanwhile the influence 
of gender and psychiatrist team toward these costs was analyzed with independent-
samples t-test. 
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4 Results  
 
The results of this study are presented in three sections. The first section shows the 
demographic and clinical features of hospitalized psychiatric patients on 
antipsychotic medication and the relationship between these characteristics. The 
second section shows the use of antipsychotic medications and other drugs 
prescribed for these patients and the factors that have a relationship with the 
prescribing patterns of antipsychotics. The last section is an economic analysis of the 
inpatient cost of treatment of psychiatric patients. 
 
4.1 Research sample 
 
In 2005, 381 patients were admitted to the Leshen Unit (Adults Psychiatry Inpatient 
Unit) AKMH. Medical records were available for review of 259 of these patients. Of 
the medical records that were reviewed, 182 cases received regular treatments of 
antipsychotic drugs. These 182 cases represented the research samples for this study. 
 
4.2 Demographic characteristics 
4.2.1 Age and gender 
The number of patients on antipsychotic medications who were males (61%) was 
significantly more than the number of females (39%) (Chi-square=8.791, df = 1, p= 
0.04) (Table 4.1). 
 
More than three quarters of the patients were less than 45 years. The age group with 
the highest number of patients was the 35 to 44 year olds (30.8%), followed by the 
25 to 34 year olds (23.6%) and the less than 25 year olds (22.5%). Overall, the mean 
age of admitted psychiatric patients was 35.9 ± 11.1 years. 
Compared with the population of Armadale
96
 aged 17 to 63 years in 2004, the 
percentages of patients aged less than 45 years (75%) was higher than population in 
those ages (55%). In the Armadale population, people aged more than 54 years had 
the highest proportion (25%) while people aged 35 to 44 and 45 to 54 year olds both 
accounted for 19% of population.  
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The age distribution of male and female patients was significantly different (chi-
square=10.258 df=4, p=0.037). More female patients (33.8%) than male patients 
(16.2%) were 45 years or older, while more male than female patients were in the 
younger than 25 year age group (27.0% vs. 15.5%) and the 35 to 44 year age group 
(34.2 vs. 25.4%) (Table 4.1). The mean age of female and male patients were 38.3 ± 
12.0 and 34.3 ± 10.3 years, respectively. 
Table 4.1 Distribution of patients according to age and gender 
 
 
 
4.3 Clinical Characteristics 
4.3.1 Length of stay (LOS) 
 
The length of stay of many patients on antipsychotic medications was less than 10 
days (43.9%), with 21.4% being admitted for 5 or fewer days and 22.5% admitted 
for 6 to 10 days (Figure 4.1). Of the patients with longer hospital episodes, 26.9% 
were admitted for between 11 and 20 days and 18.7% and 10.4% respectively for 21 
to 40 days and more than 40 days. Overall, the mean length of stay was 18.0 ± 18.3 
days. 
Age Gender Total 
Groups Female Male   
(years) N % N % n % 
<25 11 15.5 30 27.0 41 22.5 
25-34 18 25.4 25 22.5 43 23.6 
35-44 18 25.4 38 34.2 56 30.8 
45-54 16 22.5 14 12.6 30 16.5 
>54 8 11.3 4 3.6 12 6.6 
Total 71   111   182   
%   39.0   61.0   100.0 
Mean±SD 38.3±12.0 34.3±10.3 35.9±11.1 
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Figure 4. 1 Distribution of patients’ length of stay 
4.3.2 Diagnosis 
 
Of the six diagnoses for mental illness, by far the most frequently occurring one 
amongst admitted psychiatric patients treated with antipsychotic medications was 
schizophrenia (40.7%) (Figure 4.2). Almost equal numbers of psychiatric patients 
were diagnosed as having bipolar effective disorder (17.0%) and drug induced 
psychosis (13.7%), while fewer were diagnosed with depression (11.0%), with 
personality disorders (9.9%) and with miscellaneous diagnoses (7.7%).  
 
Figure 4.2 Distribution of patients by diagnosis 
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4.3.3 Psychiatrist team 
 
There were two psychiatrist teams at the AKMH, i.e. team A and team B. Both team 
A and team B comprised a consultant psychiatrist, two registrars and two medical 
officers. Psychiatric patients whose home address was north of AKMH were treated 
by team A and those who lived south of the hospital were treated by team B.  
 
The two psychiatrist teams treated almost an equal number of the admitted 
psychiatric patients with team A treating 56% of patients and team B treating 44% 
of patients (Chi-square=2.659, df=1, p=0.103). 
  
4.4 Relationship between demographics and clinical 
characteristics 
4.4.1 Length of stay and gender 
 
The distribution of length of stay of male and female psychiatric patients was similar 
(Chi-square=2.316, df=4, p=0.680) (Table 4.2).  
 
Table 4.2 Distribution of patients by length of stay and gender 
LOS Gender Total 
(days) Female Male   
 n % N % n % 
1-5 18 25.4 21 18.9 39 21.4 
6-10 18 25.4 23 20.7 41 22.5 
11-20 16 22.5 33 29.7 49 26.9 
21-40 12 16.9 22 19.8 34 18.7 
>40 7 9.9 12 10.8 19 10.4 
Total 71  111  182 100.0 
%  39.0  61.0  100.0 
Mean±SD 16.9±17.9 18.7±18. 7 18.0±18.3 
Abbreviation: LOS= length of stay 
 
 
 
 
 
  41 
4.4.2 Length of stay and age 
 
The distribution of length of hospital admission for psychiatric patients of different 
ages was similar (Chi-square= 12.582, df=9, p=0.182) (Table 4.3). Older patients 
had a slightly longer hospital stay than younger patients, with the mean length of 
stay being 21 and 19 days for patients in the 35 to 44 and 45 and over year age 
groups and 17 and 14 for patients in the less than 25 and 25 to 34 year age group 
respectively.  
 
Table 4.3 Distribution of patients by length of stay and age 
LOS Age (years) Total 
(days) <25 25-34 35-44 >44   
  n % N % N % n % n % 
1-5 9 22.0 16 37.2 8 14.3 6 14.3 39 21.4 
6-10 11 26.8 7 16.3 13 23.2 10 23.8 41 22.5 
11-20 9 22.0 13 30.2 15 26.8 12 28.6 49 26.9 
>20 12 29.3 7 16.3 20 35.7 14 33.3 53 29.1 
Total 41   43   56   42   182   
%   22.5   23.6   30.8   23.1   100.0 
Mean±SD 
(days) 17.1±17.6 13.7±16.0 21.1±21.2 19.1±16.7     
Abbreviation: LOS= length of stay 
 
 
4.4.3 Length of stay and diagnosis 
 
Patients with different diagnoses had different patterns of length of stay (Chi-
square= 45.472, df=9, p=0.000). The patients with schizophrenia and affective 
disorders had longer hospital stays than other patient (Table 4.4). While both 
schizophrenia and affective disorder patients had hospital length of stays of about 20 
days, patients with drug induced psychosis had length of stays of around 10 days 
and patients with other disorders less than 10 days.  
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Table 4.4 Distribution of patients by diagnosis and length of stay 
LOS Diagnosis Total 
(days) Schizophrenia 
Affective 
disorders* 
Drug induced 
psychosis Miscellaneous**   
 N % n % n % n % n % 
1-5 6 8.1 9 17.6 8 32.0 16 50.0 39 21.4 
6-10 10 13.5 12 23.5 9 36.0 10 31.3 41 22.5 
11-20 27 36.5 15 29.4 4 16.0 3 9.4 49 26.9 
>20 31 41.9 15 29.4 4 16.0 3 9.4 53 29.1 
Total 74   51   25   32   182   
%   40.7   28.0   13.7   17.6   100.0 
Mean±SD 23.9±19. 5 19.7±20.9 10.0±8.3 8.0±8.7   
Abbreviation: LOS= length of stay  
*Bipolar affective disorders and depression 
**Personality disorders and other disorders 
 
 
4.4.4 Length of stay and psychiatrist team 
 
The length of stay of patients who were treated by psychiatrists in team A was 
longer than for patients who were treated by psychiatrists in team B (21.06 vs. 
14.08) (Table 4.5). The percentage of patients treated in hospital for more than 40 
days by psychiatrists in team A was considerable higher than for team B (16.7% vs. 
2.5%). Meanwhile the percentage of patients treated in hospital for less than 40 days  
Table 4.5 Distribution of patients by length of stay and psychiatrist team 
LOS Psychiatrist team Total 
(days) A B   
 N % n % n % 
1-5 20 19.6 19 23.8 39 21.4 
6-10 20 19.6 21 26.3 41 22.5 
11-20 27 26.5 22 27.5 49 26.9 
21-40 18 17.6 16 20.0 34 18.7 
>40 17 16.7 2 2.5 19 10.4 
Total 102   80   182   
%   56.0   44.0   100.0 
Mean±SD 21.1±21.2 14.1±12.9     
Abbreviation: LOS= length of stay 
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by team B was considerably more for team A. As a result of these differences, the 
statistical analysis showed a statistically significant difference in the length of stay 
of patients who were treated by psychiatrist from team A compared with team B 
(Chi-square=10,007, df=4, p=0.040).  
 
4.4.5 Diagnosis and gender 
 
The number of males and females who suffered each psychiatric disorder was 
significantly different (Chi-square=16.585, df=5, p=0.004) (Table 4.6). The number 
of female patients who suffered depression, personality disorder and miscellaneous 
diagnoses (16.9%, 14.1% and 14.1 respectively) was more than for males. On the 
other hand, schizophrenia, bipolar disorder, and drug induced psychosis were 
diagnosed more in male than female patients. The most common psychiatric 
disorder in both female and male patients on antipsychotics was schizophrenia 
(29.6% and 47.7% respectively). 
 
Table 4.6 Distribution of patients by diagnosis ad gender  
Diagnosis Gender Total 
 Female Male   
 n % n % n % 
Schizophrenia 21 29.6 53 47.7 74 40.7 
Bipolar disorder 10 14.1 21 18.9 31 17.0 
Depression 12 16.9 8 7.2 20 11.0 
Drug induced 
psychosis 8 11.3 17 15.3 25 13.7 
Personality disorder 10 14.1 8 7.2 18 9.9 
Miscellaneous 10 14.1 4 3.6 14 7.7 
Total 71   111   182   
%   39.0   61.0   100.0 
 
4.4.6 Diagnosis and age 
 
The proportion of patients suffering psychiatric disorders in each age category was 
significantly different (Chi-square=37.202, df=9, p=0.000) (Table 4.7). The most 
frequently occurring diagnosis for patients aged less than 25 year olds was 
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schizophrenia (28.4%). Meanwhile drug induced psychosis was the most frequently 
occurring diagnosis for patient aged 25 to 34 years; and affective disorders was the 
most common for patients aged more than 35 years.  
 
Table 4.7 Distribution of patients by diagnosis and age 
Age Diagnosis  Total 
(years) Schizophrenia 
Affective 
disorders* 
Drug induced 
psychosis Miscellaneous**   
 n % n % n % N % n % 
<25 21 28.4 6 11.8 5 20.0 9 28.1 41 22.5 
25-34 16 21.6 6.0 11.8 15 60.0 6.0 18.8 43 23.6 
35-44 24 32.4 18 35.3 5 20.0 9 28.1 56 30.8 
>44 13 17.6 21 41.2 0 0.0 8 25.0 42 23.1 
Total 74  51  25  32  182  
%  40.7  28.0  13.7  17.6  100.0 
Mean±SD  34.2±10.1 41.7±11.6 29.4±6.2 35.7±11.7     
*Bipolar affective disorders and depression 
**Personality disorders and other disorders 
 
Patients with drug induced psychosis had the lowest mean age (29.4 years); in 
contrast patients with affective disorders were the oldest (41.7 years). The age of 
patients with other disorders was similar at approximately 35 years. 
 
4.4.7 Diagnosis and psychiatric team 
 
The pattern of diagnoses of the patients who were treated by psychiatrist team A and 
psychiatrist team B was not statistically significantly different (Chi-square=8.433, 
df=5, p=0.139), although differences did exist. Forty eight percent of patients who 
were treated by team A were diagnosed with schizophrenia while less than one third 
of patients treated by team B were diagnosed with this disorder. The percentage of 
patients with bipolar disorder, depression, drug induced psychosis, and personality 
disorder in team A was significantly less than those in team B (11.8% vs. 23.8%, 
10.8% vs. 11.3%, 12.7% vs. 15% and 7.8% vs. 12.5% respectively). On the other 
hand, team A took care of patients with miscellaneous diagnosis more than team B 
(8.8% vs.6.3%). (Table 4.8) 
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Table 4.8 Distribution of patients by diagnosis and psychiatrist team 
Diagnosis Psychiatrist team Total 
 A B   
 N % n % n % 
Schizoprenia 49 48.0 25 31.3 74 40.7 
Bipolar disorder 12 11.8 19 23.8 31 17.0 
Depression 11 10.8 9 11.3 20 11.0 
Drug induced 
psychosis 13 12.7 12 15.0 25 13.7 
Personality disorder 8 7.8 10 12.5 18 9.9 
Miscellaneous 9 8.8 5 6.3 14 7.7 
Total 102  100.0 80 100.0  182 100.0  
% treated   56.0   44.0   100.0 
  
 
4.5 Pattern of use of psychotropic and other medications for 
treating psychiatric patients  
 
Table 4.9 and Table 4.10 show drugs that were used by psychiatric inpatients in this 
study. Table 4.9 includes only drugs that were used as regular treatments, while 
Table 4.10 includes use of regular treatments as well as ‘as needed” or pro re nata 
(PRN) medications.  
 
4.5.1 Pattern of drugs as regular treatments  
4.5.1.1 Pattern of antipsychotic medications as regular treatment 
 
Antipsychotic medications were the most often drug used for treating the patients, 
accounting for around 35% of the drugs used. Of these drugs, 32.9% was atypical 
antipsychotic drugs and only 2.9% were typicals.  
 
Olanzapine was the atypical antipsychotic that was most often used as routine 
antipsychotics with 91 patients treated with this drug; followed by quetiapine and 
risperidone (52 and 46 cases respectively). Typical drugs that were the most 
frequently used were chlorpromazine (six patients), trifluorperazine (four patients), 
zuclopenthixol (three patients) and haloperidol (three patients). 
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Combinations of quetiapine-olanzapine (10 cases) and risperidone-olanzapine (10 
cases) were the most common combinations of two atypicals. The combination of 
quetiapine with risperidone and amilsulpride with clozapine were found in five cases 
and four cases respectively. Antipsychotic polytherapy with three atypicals most 
generally used a combination of quetiapine-risperidone-olanzapin and quetiapine-
olanzapine-clozapine, each these combinations being used for two cases.  
 
Chlorpromazine (two cases) and trifluorperazine (two cases) were the typical 
antipsychotics that were most common used as regular typical monotherapy. These 
drugs and other typicals, such as, zuclopenthixol decanoate, haloperidol, pimozide 
and pericyazine were also used as monotherapy and polytherapy antipsychotics by 
combining with other atypical or typical medications. 
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Table 4.9 Antipsychotic and other medications for treating hospitalized psychiatric patients in 2005 as regular use 
Type of drug   The most commonly used drugs* 
 % Drug 1 n Drug 2 N Drug 3 n 
Atypical Antipsychotics 32.6 Olanzapine 91 Quetiapine 52 Risperidone 46 
Typical antipsychotics 2.9 Chlorpromazine 6 Triflourperazine 4 Zuclopenthixol  3 
Anxiolytics & hipnotics 19.0 Temazepam  40 Lorazepam 33 Clonazepam 22 
Antidepressant 9.2 Mirtazepin 17 Venlafaxine 8 Sertraline 8 
Mood stabilizers 10.1 Sodium valproate 42 
Lithium 
carbonate 9 Carbamazepine 7 
Anticholinergics 1.6 Benztropine 11  -    -   
Analgesics 2.2 Ibuprofen  5 Paracetamol 2 Panadeine 2 
Gastrointestinal drugs 3.7 Esomeprazole 4 Omeprazole 4 Loperamide 3 
Vitamins 4.8 Thiamine 12 Multivitamin 9 Folic acid 4 
Cardiovascular drugs 3.8 Simvastatin 9 Propanolol 8 Atorvastatin 3 
Respiratory drugs 1.9 Fluticasone 8 Salbutamol SO4 3 Ipratropium 2 
Antibacterials 2.6 Amoxicillin 8 Trimethorpin 2 Flucloxacillin 2 
Others 5.3 Metformin 6 Nystatin 4 FeSO4 4 
Total 100.0             
* Patients could receive more than one medication. 
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4.5.1.2 Patterns of other medications as regular use 
 
In regular treatment, anxiolytic and hypnotic medications were the second type of 
drugs that were most often used (19%). In this class of drugs, temazepam (40 cases) 
was the most frequent used, followed by, lorazepam (33 cases), clonazepam (22 
cases), diazepam (nine cases) and nitrazepam (six cases). 
 
Antidepressants accounted for around 9.2% of the drugs. The most often 
antidepressant used was mirtazepine (17 patients); with venlafaxine and sertraline 
used by eight patients. Other antidepressants such as fluoxetine, citalopram, 
clomipramine, escitalopram oxalate, and mianserin were used less frequently than 
those three drugs. Meanwhile, sodium valproate (42 patients) was the most frequent 
mood stabilizer used, followed by lithium carbonate (nine patients), and 
carbamazepine (seven patients).  
 
Anticholinergic medication for treating extrapyramidal side effect accounted for 
1.5% of drugs used with only benztropine used regularly (11 patients). 
 
Non psychotropic medications are drugs for treating comorbidities. Including in this 
group are gastrointestinal drugs, cardiovascular drugs, respiratory drugs, analgesics, 
vitamins, antibacterials, cardiovascular drugs, antidiabetics etc. These drugs 
accounted for 24.3% of all drug used by the patients. 
 
4.5.2 Pattern of psychotropic drugs as regular treatments and PRN 
medications 
 
Table 4.10 shows the drugs for psychiatric patients in this study including drugs that 
were given to the patients when they needed those drugs (PRN use). Psychotropics 
that were sometimes given as PRN drugs were antipsychotic, anxiolytic and 
hypnotic and anticholinergic medications, while non-psychotropic drugs that were 
usually used as needed drugs were analgesics and salbutamol inhalers. 
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4.5.2.1 Patterns of antipsychotic medications as regular and as PRN 
use 
 
 Atypical antipsychotic agents most commonly prescribed as PRN use were 
olanzapine and quetiapine. These two drugs were prescribed as PRN  for 12 cases. 
In the typical group, chlorpromazine was the most frequently prescribed drug for 
PRN , with it being used for 21 cases. Four patients also were treated with 
droperidol as PRN use.  
 
The patterns of antipsychotic use were changed when PRN use was included in the 
overall analysis. Olanzapine, quetiapine and risperidone were still the three most 
often monotherapy atypicals for treating patients. One hundred and three patients 
used olanzapine; 64 and 46 patients were treated with quetiapine and risperidon 
respectively. Chlorpromazine as typical monotherapy was used in 27 patients.  
 
Olanzapine was the most frequently used in combinations of two atypicals. It was 
combined with quetiapine in 15 patients, with five of these patients getting 
quetiapine as PRN drugs. Olanzapine was combined with with risperidone for 
treating 15 patients and olanzapine was given as needed drug for seven of those 
patients.   
 
Besides olanzapine, quetiapine was also used as two atypicals with other 
antipsychotics. Eight patients were treated with quetiapine-risperidone and three of 
them got quetiapine as PRN drug. Two of four patients on a combination of 
aripiprazole and quetiapine also got a PRN quetiapine.  
 
Olanzapine was the most often antipsychotic combining with more than two other 
antipsychotics. Olanzapine with quetiapine and chlorpromazine was used for five 
patients with three of these patients getting chlorpromazine as a PRN drug. There 
was also a combination of olanzapine with quetiapine and risperidone, with 
chlorpromazine and droperidol, amisulpride and chlorpromazine, and with 
quetiapine and zuclopenthixol.  
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Chlorpromazine as typical antipsychotics was frequently used as a PRN drug and 
combined with other antipsychotics. Only one case was on olanzapine and 
chlorpromazine as a regular drug but chlorpromazine as PRN drug combined with 
olanzapine was used in five cases. Chlorpromazine as PRN drug also was combined 
with amilsulpride (four cases), risperidone (three cases) and quetiapine (one case). 
Chlorpromazine was used with two or more antipsychotics usually also as a PRN 
drug. 
 
A few patients in this study got droperidol as PRN use. Four patients used this drug, 
either in a combination of droperidol with olanzapin and chlorpromazine (three 
patients) or risperidone and chlorpromazine (one patient). Chlorpromazine used by 
those patients was also as PRN drug. 
 
Other typicals, such as haloperidol, zuclopenthixol decanoate, triflouperazine, 
pericyazine, and pimozide were regular drugs. They usually were combined with 
other antispychotics. Zuclopenthixol decanoate and droperidol were an intra 
muscular injection. 
 
4.5.2.2 Patterns of other medications as regular and as PRN use 
 
The number of patients receiving anxiolytic and hypnotic drugs as PRN prescription 
were extremely high. The number of patients getting lorazepam (58 patients) and 
clonazepam (44 patients) as PRN medications was approximately twice the number 
cases using these drugs as routine prescriptions (33 and 22 patients, respectively). 
The number of patients treated regularly with temazepam was similar with those 
with PRN use (around 40 patients). 
 
The use of anticholinergic medication as PRN medication was also high, with 19 
patients in this category.  
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Table 4.10 Psychotropic and other medications for treating hospitalized psychiatric patients in 2005 as regular and PRN use 
Type of drug   The most commonly used drugs* 
 % Drug 1 n Drug 2 n Drug 3 n 
Atypical Antipsychotics 27.3 Olanzapine** 103 Quetiapine**  64 Risperidone 46 
Typical antipsychotics 4.8 Chlorpromazine** 27 Triflouperazine 4 Droperidol** 4 
Anxiolytics & hipnotics 29.3 Temazepam ** 79 Lorazepam ** 91 Clonazepam** 66 
Antidepressant 6.5 Mirtazepin 17 Venlafaxine 8 Sertraline 8 
Mood stabilizers 6.6 Sodium valproate 42 Litrium carbonate 9 Carbamazepine 7 
Anticholinergics 2.2 Benztropine** 20  -    -   
Analgesics 4.0 Paracetamol** 14 Panadeine** 10 Ibuprofen** 6 
Gastrointestinal drugs 3.5 Esomeprazole 4 Omeprazole 4 Loperamide 3 
Vitamins 3.5 Thiamine 12 Multivitamin 9 Folic acid 4 
Cardiovascular drugs 3.1 Simvastatin 9 Propranolol 8 Atorvastatin 3 
Respiratory drugs 2.7 Salbutamol SO4** 13 Fluticasone 8 Beclomethasone 2 
Antibacterials 2.0 Amoxicillin 8 Trimethoprin 2 Flucloxacillin 2 
Others 5.3 Metformin 6 Nystatin 4 FeSO4 4 
Total 100             
* Patients could receive more than one medication. 
** including regular and PRN (as needed) uses 
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Non anti psychotropic drugs that were used as PRN drugs in this study were 
analgesics, such as paracetamol, panadeine and ibuprofen and salbutamol sulphate 
inhaler. There were 13 patient treated with paracetamol as needed drug, eight 
patients with panadeine, one patient with ibuprofen and 10 patients with salbutamol 
sulphate inhaler. 
 
4.6 Association between patterns of use of antipsychotic 
medications and patients’ characteristics. 
 
Chi-squared tests and multinomial logistic analyses were conducted to examine 
whether there was a significant association between patterns of antipsychotic use 
and demographic and clinical characteristics. The patterns of antipsychotic use were 
classified into five group and categories of age, length of stay and diagnoses were 
transformed into three categories in order to meet with chi-square assumption, in 
which no more than 20% of the cells have expected frequency less than five.
94, 97
  
 
4.6.1 Patterns of antipsychotic use excluding PRN antipsychotics 
 
The classification of antipsychotic medication use in Table 4.11 was based on the 
antipsychotics that were used as regular medications. The patterns of use of 
antipsychotic medications did not differ significantly between male and females, 
age, length of stay categories and psychiatrist teams.  
 
The only statistically significant difference in the pattern of use of antipsychotic 
medications was for diagnosis (p=0.001). The main difference was found between 
schizophrenia and the other diagnoses. Patients with schizophrenia were treated 
relatively more frequently with risperidone, combination atypicals and other 
monotherapy atypicals than patients with affective disorder and miscellaneous 
disorders. On the other hand, patients with affective disorder and miscellaneous 
disorders were treated relatively more frequently with olanzapine and quetiapine. 
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Table 4.11 Distribution of patients’ characteristics by antipsychotic use (excluding PRN antipsychotics) 
Characteristics Antipsyhotic medications Total     
 
 
Olanzapine Quetiapine Risperidone 
Combination 
atypical 
Other 
monotherapy 
atypical Typicals 
Combinatio
n typical-
atypical   
Chi-
square* 
p-
value* 
 N % n % n % N % N % n % n % n %   
Gender Female 22 31.0 13 18.3 10 14.1 14 19.7 5 7.0 4 5.6 3 4.2 71 39.0 4.704 0.327 
 Male 38 34.2 9 8.1 14 12.6 28 25.2 12 10.8 4 3.6 6 5.4 111 61.0   
Age <35 26 31.0 6 7.1 13 15.5 21 25.0 10 11.9 2 2.4 6 7.1 84 46.2 6.172 0.635 
(years) 35-44 17 30.4 10 17.9 7 12.5 12 21.4 5 8.9 3 5.4 2 3.6 56 30.8   
 >44 17 40.5 6 14.3 4 9.5 9 21.4 2 4.8 3 7.1 1 2.4 42 23.1   
 Mean±SD 37.17±11.39 38.09±9.75 33.54±10.60 35.19±11.60 32.29±9.58 41.13±12.81 33.22±11.8     
LOS 1-5 10 25.6 8 20.5 5 12.8 6 15.4 5 12.8 2 5.1 3 7.7 39 21.4 10.350 0.242 
(days) 6-10 17 41.5 4 9.8 2 4.9 10 24.4 3 7.3 4 9.8 1 2.4 41 22.5   
 >10 33 32.4 10 9.8 17 16.7 26 25.5 9 8.8 2 2.0 5 4.9 102 56.0   
 Mean±SD 14.83±12.43 18.0±19.24 25.42±23.44 22.29±23.84 14.12±10.95 8.25±6.43 15.11±15.71     
Diagnosis Schizophrenia 16 21.6 2 2.7 15 20.3 26 35.1 11 14.9 1 1.4 3 4.1 74 40.7 27.813 0.001 
 
Affective 
disorder** 22 43.1 10 19.6 4 7.8 8 15.7 2 3.9 3 5.9 2 3.9 51 28.0   
  
Miscellaneous**
* 22 38.6 10 17.5 5 8.8 8 14.0 4 7.0 4 7.0 4 7.0 57 31.3     
Psychiatrist A 30 29.4 13 12.7 18 17.6 27 26.5 7 6.9 3 2.9 4 3.9 102 56.0 8.682 0.67 
Team B 30 37.5 9 11.3 6 7.5 15 18.8 10 12.5 5 6.3 5 6.3 80 44.0     
 Total 60   22   24   42   17   8   9   182     
  %   33.0   12.1   13.2   23.1   9.3   4.4   4.9   100.0     
LOS= length of stay 
*other monotherapy atypical, typical and combination of typical-atypical were combined to meet the assumptions of chi-square test   
** bipolar affective disorders, depression 
*** drug induced psychosis, personality disorder, other disorders 
  54 
4.6.2 Patterns of antipsychotic use including PRN antipsychotics 
 
Several patients got olanzapine, quetiapine, chlorpromazine or droperidol as PRN 
drugs; which changed the number of patients treated with each of the antipsychotic 
categories (Table 4.12). The number of patients on atypical monotherapy and 
typicals monotherapy decreased while the number of patients on combination 
atypical and combination atypical-typical increased.  
 
The patterns of use of antipsychotic medications did not differ significantly by 
gender, age or length of stay categories, but did differ significantly by diagnosis and 
treatment team.  
 
A statistically significant association was found between the pattern of antipsychotic 
medications and diagnosis. Patients with schizophrenia were most commonly treated 
with a combination of atypicals (44.6%), with the next most common treatment 
being olanzapine (16.2%). Patients with affective disorders and miscellaneous 
diagnoses were most commonly treated with olanzapine (33.3% and 29.8% 
respectively) followed by a combination of atypicals (19.6% and 19.3% respectivey) 
and quetiapine (15.7% and 15.8% respectively).  
 
When PRN antipsychotic use was also included in the classification of antipsychotic 
use, there was a highly statistically significant association between the patterns of use 
and psychiatrist team (p<0.001). Team A prescribed relatively more combination 
atypicals and fewer combination atypical-typicals than Team B. Furthermore, no 
cases treated by Team B were treated with risperidone.  
 
.  
. 
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Table 4.12 Distribution of patients’ characteristics by antipsychotic use (including prn antipsychotics) 
Characteristics Antipsychotic medications Total     
  Olanzapine Quetiapine Risperidone 
Combination 
atypicals 
Other 
atypical 
monotherapy Typicals 
Combination 
atypical 
typical   
Chi-
square* 
p-
value* 
  n % N % n % n % N % N % n % n %   
Gender Female 18 25.4 11 15.5 5 7.0 20 28.2 5 7.0 3 4.2 9 12.7 71 39 3.663 0.453 
 Male 28 25.2 8 7.2 7 6.3 34 30.6 8 7.2 4 3.6 22 19.8 111 61   
Age <35 19 22.6 5 6.0 6 7.1 28 33.3 8 9.5 2 2.4 16 19.0 84 46 7.924 0.444 
(years) 35-44 13 23.2 10 17.9 3 5.4 14 25.0 4 7.1 3 5.4 9 16.1 56 31   
 >44 14 33.3 4 9.5 3 7.1 12 28.6 1 2.4 2 4.8 6 14.3 42 23   
  Mean±SD 38.04±11.44 37.32±9.89 36.42±11.07 34.2±11.94 32.23±9.471 38.0±10.02 35.48±10.78       
LOS 1-5 7 17.9 7 17.9 3 7.7 9 23.1 3 7.7 1 2.6 9 23.1 39 21 9.881 0.276 
(days) 6-10 14 34.1 3 7.3 0 0.0 14 34.1 2 4.9 4 9.8 4 9.8 41 23   
 >10 25 24.5 9 8.8 9 8.8 31 30.4 8 7.8 2 2.0 18 17.6 102 56   
 Mean±SD 15.43±13.45 18.95±20.33 32.42±29.11 17.59±16.85 16.69±11.03 9.14±6.39 18.84±22.9     
Diagnosis Schizophrenia 12 16.2 2 2.7 7 9.5 33 44.6 9 12.2 1 1.4 10 13.5 74 41 23.35 0.003 
 
Affective 
disorder** 17 33.3 8 15.7 1 2.0 10 19.6 2 3.9 2 3.9 11 21.6 51 28   
  Miscellaneous*** 17 29.8 9 15.8 4 7.0 11 19.3 2 3.5 4 7.0 10 17.5 57 31     
Psychiatrist A 27 26.5 12 11.8 12 11.8 33 32.4 5 4.9 2 2.0 11 10.8 102 56 19.41 <0.001 
Team B 19 23.8 7 8.8 0 0.0 21 26.3 8 10.0 5 6.3 20 25.0 80 44   
  Total 46 25.3 19 10.4 12 6.6 54 29.7 13 7.1 7 3.8 31 17.0 182 100     
  %   25.3   10.4   6.6   29.7   7.1   3.8   17.0   100     
LOS= length of stay   
*other monotherapy atypical, typical and combination of typical-atypical were combined to meet the assumptions of chi-square test   
** bipolar affective disorders, depression   
*** drug induced psychosis, personality disorder, other disorders     
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4.6.3 Factors associated with the patterns of antipsychotic medication 
use 
 
Multinomial logistic regression analysis was conducted to further investigation the 
factors associated with patterns of antipsychotic use.  
 
4.6.3.1 Factors associated with the patterns of antipsychotic use 
(excluding PRN use) 
 
The results of the multinomial logistic regression are presented in Table 4.13 and 
Table 4.14.  The results of the likelihood ratio tests (Table 4.13) indicated that 
diagnosis was the only factor associated with antipsychotic use if the classification 
of antipsychotic use patterns excluded the PRN antipsychotics. The output further 
suggested that the odds were statistically significantly higher that schizophrenic 
patients versus patients with miscellaneous diagnosis would be treated with 
risperidone rather than olanzapine (4.348; 95% CI 1.083-17.463) (Table 4.14) and 
with combination atypicals than olanzapine (5.388; 95% CI 1.680-17.277).  
 
Table 4.13 Likelihood Ratio Tests 
Characteristic/Variable 
-2 Log Likelihood 
Reduced Chi-Square Df p 
Gender 
338.899 3.533 4 0.473 
Age (years) 
341.858 6.492 8 0.592 
LOS (days) 
343.648 8.283 8 0.406 
Diagnosis 
359.017 23.651 8 0.003 
Psychiatrist team 
342.725 7.359 4 0.118 
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Table 4.14 Multinomial logistic regression analysis of patterns of antipsychotic 
use (excluding PRN antipsychotics) 
 
Antipsychotic Characteristic/ 
Variable 
P Odds 
Ratio 
95% 
Confidence Interval 
Risperidone Diagnosis: 
Schizophrenia  
Affective disorders 
Miscellaneous* 
 
0.038 
0.908 
- 
 
4.349 
1.097 
- 
 
1.083-17.463 
0.225-5.346 
- 
Combination 
atypical 
Diagnosis: 
Schizophrenia  
Affective disorders 
Miscellaneous* 
 
0.005 
0.678 
- 
 
5.388 
1.302 
 
1.680-17.277 
0.374-4.534 
Olanzapine is the reference category of antipsychotic pattern 
* drug induced psychosis, personality disorder, miscellaneous 
 
 
4.6.3.2 Factor associated with the patterns of antipsychotic use 
(including PRN use) 
 
Tables 4.15 and 4.16 repeat the above analyses including PRN use of antipsychotics.  
Table 4.15 confirms a statistically significant association between both diagnosis 
and psychiatrist team and the pattern of antipsychotic use. The odds were 6.178 
(95% CI 1.927-19.807) times higher of treating with combination atypical over 
olanzapine if the diagnosis was schizophrenia versus miscellaneous diagnoses 
(Table 4.16). The odds of choosing olanzapine versus miscellaneous antipsychotics 
by psychiatrist team B was 2.915 (CI 1.228-6.896) higher than the odds for team A. 
 
 
Table 4.15 Likelihood Ratio Tests 
Characteristic/Variable 
-2 Log Likelihood 
Reduced Chi-Square df p 
Gender 308.003 2.771 4 0.597 
Age (years) 314.766 9.534 8 0.299 
LOS (days) 317.726 12.493 8 0.130 
Diagnosis 329.348 24.116 8 0.002 
Psychiatrist team 328.502 23.269 4 0.0001 
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Table 4.16 Multinomial logistic regression analysis of patterns of antipsychotic 
use pattern (including PRN antipsychotics) 
 
Antipsychotic Characteristic/ 
Variable 
p Odds 
Ratio 
95% 
Confidence Interval 
Combination 
atypical 
Diagnosis: 
Schizophrenia  
Affective disorders 
Miscellaneous* 
 
0.002 
0.750 
- 
 
6.178 
1.216 
 
1.927-19.807 
0.366-4.043 
Miscellaneous** Psychiatrist team 
B 
A 
 
0.015 
- 
 
2.915 
 
1.228-6.896 
Olanzapine is the reference category of antipsychotic pattern 
* drug induced psychosis, personality disorder, miscellaneous 
** other monotherapy atypical, typical, combination atypical-typical 
 
 
4.7 Economic analysis 
 
The cost of drugs was calculated using both drugs as regular and PRN use in the 
economic analysis. 
 
4.7.1 Total mean costs by cost category  
 
Several factors influenced the cost of treating patients (Table 4.17). In terms of total 
cost, the mean cost of treating male patients was higher than female patients and 
patients in the 35 to 44 year age group had a higher mean cost than patients in other 
age groups. Increasing the length of stay caused the mean cost to increase. Patients 
with schizophrenia had a higher mean cost than patients with other diagnoses, while 
patients who were treated by psychiatrist team A had a higher mean cost than those 
treated by team B. If patients are grouped by antipsychotic use, patients on 
combination atypicals had the highest mean cost. 
 
The cost of individual cost categories was also investigated. In general, the 
differences in total cost by demographic, clinical and treatment factors discussed 
above were maintained for the different cost categories but with some interesting 
findings. The mean cost of antipsychotic medications varied considerably across 
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patients based on treatment group. The mean cost of patients on combination 
atypicals was $174.39 compared with $73.07 for patients on  risperidon  oral  and  
 
Table 4.17 Distribution of mean cost amongst demographic and clinical 
characteristics 
Characteristics Mean Cost (A$) 
   
Antipsy-
chotics 
Psycho-
tropics 
All 
drugs 
Laboratory 
tests 
Bed 
days Total 
Gender               
Male Mean 162.04 181.56 191.99 152.54 6545.95 7234.07 
  SD 208.62 234.08 251.40 99.75 6535.74 7150.28 
Female Mean 92.30 107.47 117.96 145.57 5905.63 6368.93 
  SD 130.34 138.00 147.87 94.55 6247.54 6521.45 
Age (years)       
<35 Mean 129.13 142.00 147.59 141.35 5379.17 5939.24 
 SD 192.92 207.29 213.61 98.60 5872.92 6427.29 
35-44 Mean 158.79 185.33 198.73 145.45 7387.50 8075.80 
 SD 203.34 239.64 265.66 102.05 7434.12 8014.92 
>44 Mean 114.29 130.40 146.65 172.59 6675.00 7238.94 
  SD 137.18 138.16 152.09 87.49 5849.67 6072.16 
LOS (days)       
1-5 Mean 19.83 22.90 26.41 104.25 1023.08 1196.47 
 SD 15.08 16.91 21.40 74.17 470.84 499.61 
6-10 Mean 58.76 66.95 72.51 147.20 2774.39 3119.81 
 SD 56.90 59.21 60.70 76.98 465.58 537.01 
>10 Mean 209.38 236.72 251.79 168.30 9727.94 10594.14 
  SD 216.38 238.98 257.32 107.18 6776.08 7288.83 
Diagnosis        
Schizophrenia Mean 207.82 225.25 232.92 155.55 8347.97 9169.50 
 SD 217.44 235.75 241.78 107.44 6807.41 7301.52 
Affective 
disorders Mean 129.64 159.02 181.14 160.03 6876.47 7506.30 
  SD 183.89 217.65 253.06 95.76 7298.76 7866.85 
Others Mean 44.72 52.73 56.35 133.26 3113.16 3400.21 
  SD 57.68 61.39 63.22 84.29 2976.24 3131.54 
Psychiatrist team       
A Mean 140.42 163.00 177.16 144.42 7370.59 7995.59 
  SD 183.69 209.82 228.39 100.13 7421.00 7933.16 
B Mean 127.70 139.47 145.19 156.71 4926.25 5495.33 
  SD 187.31 198.94 207.63 94.33 4526.52 5027.34 
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Table 4.17 Distribution of mean cost amongst demographic and clinical 
characteristics (continued) 
Characteristics Mean Cost (A$) 
   
Antipsy-
chotics 
Psycho-
tropics 
All 
drugs 
Laboratory 
tests Bed days Total 
Antipsychotic medications      
Olanzapine Mean 93.10 112.02 120.79 157.07 5402.17 5885.16 
 SD 98.89 113.25 118.31 73.01 4708.28 4911.60 
Quetiapine Mean 103.12 126.98 140.63 172.31 6631.58 7174.63 
  SD 159.19 188.99 209.48 107.78 7117.12 7744.42 
Risperidone* Mean 96.56 106.29 106.63 133.57 10446.15 10889.21 
 SD 116.71 118.67 118.45 100.08 9475.72 9813.66 
Combination Mean 174.39 191.82 202.17 138.18 6008.33 6714.89 
Atypicals SD 213.26 231.83 240.90 97.19 5796.62 6346.08 
Others** Mean 152.50 169.56 183.07 151.39 6223.00 6879.53 
 SD 225.81 253.42 279.22 113.36 7018.29 7720.27 
Risperidone Mean 73.07 86.60 88.78 146.81 8895.83 9384.56 
per oral SD 99.80 106.53 106.36 91.71 8204.93 8511.68 
Other  mono- Mean 86.50 93.60 95.03 153.07 4941.18 5369.38 
Therapy 
atypical SD 82.39 85.14 85.68 144.58 3831.83 4081.86 
Typicals Mean 3.85 8.11 9.78 149.57 2887.50 3058.80 
  SD 3.95 9.23 8.62 79.76 2250.83 2306.49 
Combination Mean 252.04 276.20 295.64 90.21 5288.89 6202.98 
atypical-typical SD 274.28 301.71 329.56 79.68 5499.14 6331.34 
* included risperidone extended release (consta) 
** typicals, other atypical monotherapy, combination typical-atypical 
 
$3.85 for patients on typical antipsychotics. A similar pattern of differences in mean 
cost between patient groups was evident for antipsychotic medications. There were 
also interesting differences in the pattern of mean costs between the two teams. 
Patients treated by Team A had a considerably higher mean bed day cost than those 
treated by Team B while patients treated by Team B had a slightly higher mean cost 
for laboratory tests.  
 
4.7.2 Relationship between the mean cost of antipsychotic agents and 
patients’ characteristics 
 
Because the cost data was not normally distributed, a natural logarithmic 
transformation was performed to normalize the cost measures.
93
 The transformed 
data was analyzed with one-way analysis of variance with post-hoc comparison to 
determine whether age, length of stay, diagnosis and pattern of antipsychotic use 
influenced the antipsychotic, psychotropic, all drug and total costs.  Meanwhile the 
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influence of gender and psychiatrist team toward these costs was analyzed with 
independent-samples t-test.  
 
The independent-sample t-test of the mean cost of antipsychotic drugs found a 
statistically difference between female ($92.30±130.34) and male patients ($162.04± 
208.62) (t=-3.267, p=0.001). The one-way analysis of variance of this mean cost  
showed statistically significant differences between patients in the different length of 
stay groups (F=46.710, p<0.001), by diagnosis (F=28.832; p<0.001) and pattern of 
antipsychotic use (F=3.181, p<0.015) (Table 4.18). These differences were further 
explored by conducting post-hoc comparisons using the Least Significant Difference 
(LSD) test.  
 
Table 4.18 Analysis of the mean cost of antipsychotic medications 
Independent variables T F p-value 
Gender -3.267  0.001 
Psychiatrist team 0.551  0.582 
Age (years)  0.736 0.481 
Length of stay (days)  46.710 0.000 
Diagnosis  28.832 0.000 
Antipsychotic use pattern  3.181 0.015 
 
 
In terms of length of stay, the results indicated that the mean cost of antipsychotic 
medications for patients admitted for more than 10 days ($209.38±$216.38) was 
statistically significantly higher than for the two other LOS groups ($19.83±$15.08 
and $58.76, ±$56.90) and that for patients admitted for 6 to 10 days was statistically 
significantly higher than for patients admitted for 5 or less days (Table 4.19). 
 
Table 4.19 Post hoc test (Least Significant Difference) of the cost of 
antipsychotic medications cost based on patients’ length of stay 
(I) 
LOS 
(J) 
LOS 
Mean Difference 
(I-J) p-value 
95% Confidence 
Interval  
1-5 6-10 -0.832 0.004* -1.390 -0.275 
 >10 -2.163 0.000* -2.632 -1.694 
6-10 1-5 0.832 0.004* 0.275. 1.390 
  >10 -1.331 0.000* -1.792 -0.870 
>10 1-5 2.163 0.000* 1.694 2.632 
  6-10 1.331 0.000* 0.870 1.792 
*Mean difference is significant at .05 ...  
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In the case of type of antipsychotic medication, the mean cost of patients on 
combination atypical ($174.39±$213.26) was statistically significantly higher than 
on olanzapine ($93.10±98.89), quetiapine ($103.12±159.19) and risperidone 
(96.56±116.71) (p<0.05) but it was not difference with other groups 
($152.50±225.81) (Table 4.20). 
 
Table 4.20 Post hoc test (Least Significant Difference) of the cost of 
antipsychotic medications based on the pattern of antipsychotic use 
(I) Antipsychotics (J) Antipsychotics 
Mean 
Difference 
(I-J) p-value 
95% Confidence 
Interval for 
Difference 
Others Olanzapin only 0.784 0.059 -0.031 1.598 
 Quetiapine only 0.226 0.467 -0.385 0.836 
 Risperidon only 0.667 0.163 -0.272 1.605 
  Combination atypical -0.428 0.160 -1.028 0.171 
olanzapin only Others -0.784 0.059 -1.598 0.031 
 Quetiapine only -0.558 0.173 -1.363 0.247 
 Risperidon only -0.117 0.830 -1.192 0.958 
 Combination atypical -1.212 0.003* -2.009 -0.416 
quetiapine only Others -0.226 0.467 -0.836 0.385 
 Olanzapin only 0.558 0.173 -0.247 1.363 
 Risperidon only 0.441 0.351 -0.489 1.371 
  Combination atypical -0.654 0.029* -1.240 -0.067 
risperidon only Others -0.667 0.163 -1.605 0.272 
 Olanzapin only 0.117 0.830 -0.958 1.192 
 Quetiapine only -0.441 0.351 -1.371 0.489 
 Combination atypical -1.095 0.02* -2.018 -0.172 
combination 
atypical Others 0.428 0.160 -0.171 1.028 
 olanzapin only 1.212 0.003* 0.416 2.009 
 Quetiapine only 0.654 0.029* 0.068 1.240 
  Risperidon only 1.095 0.020* 0.172 2.018 
*Mean difference is significant at .05 ...   
 
 
Statistically significant differences were also found between diagnosis (p<0.05). 
Schizophrenia had the highest cost ($207.82±$217.44), followed by affective 
disorders ($129.64±$183.89) and other diagnoses ($44.72 ±$57.68) (Table 4.21). 
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Table 4.21 Post hoc test (Least Significant Difference) of the cost antipsychotic 
medications based on diagnosis 
(I) diagnosis (J) diagnosis 
Mean Difference 
(I-J) p-value 
95% Confidence 
Interval  
schizophrenia 
Affective 
disorder 0.896 0.000* 0.410 1.383 
 Miscellaneous 1.810 0.000* 1.338 2.281 
Affective 
disorder Schizophrenia -0.896 0.000* -1.383 -0.410 
  Miscellaneous 0.913 0.001* 0.398 1.429 
miscellaneous Schizophrenia -1.810 0.000* -2.281 -1.339 
  
Affective 
disorder -0.913 0.001* -1.429 -0.398 
*Mean difference is significant at .05 ... 
 
 
4.7.3 Relationship between the mean cost of psychotropic agents and 
patients’ characteristics 
 
The mean of cost of psychotropic drugs for treating female ($107.47±138.00) and 
male patients ($181.56±234.08) was statistically significantly different (t=-2.867, 
p=0.005). The one-way analysis of variance of the mean cost of psychotropic agents 
showed statistically significant differences in the mean cost for patients in the 
different length of stay groups (F=65.145, p<0.001), by diagnosis (F=27.664, 
p<0.001) and by antipsychotic use pattern (F=2.12, p=0.080) (Table 4.22). 
 
Table 4.22 Analysis of the mean cost of psychotropic agents 
Independent variables T F p-value 
Gender -2.867  0.005 
Psychiatrist team 0.641  0.522 
Age (years)  0.939 0.393 
Length of stay (days)  65.145 0.000 
Diagnosis  27.664 0.000 
Antipsychotic use 
pattern 
 
2.121 0.080 
 
Again these differences in mean cost were further explored. The result of the LSD 
test indicated that the mean cost of psychotropic agents between LOS groups were 
statistically significantly different (Table 4.23). The mean cost for patients with a 
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LOS of 6 to 10 days ($66.95±$59.21) was around three fold that of patients with a 
LOS of 1 to 5 days ($22.90±$16.91). Patients hospitalized for more than 10 days 
also had a mean cost that was statistically significantly higher ($236.72±$238.98) 
than the mean costs for patients in the other two LOS groups.  
 
Table 4.23 Post hoc test (Least Significant Difference) of the cost of 
psychotropic agents based on patients’ length of stay 
 
 
In relation to differences in the cost of psychotropic agents for patients with different 
diagnoses, the mean cost for patients suffering schizophrenia was statistically 
significantly higher ($225.25±$235.75) than for patients with affective disorder 
($159.02±$217.65) and other diagnoses ($52.73±$61.39) and was higher for patients 
with affective disorder than those with in the miscellaneous diagnosis category 
(Table 4.24). 
 
Table 4.24 Post hoc test (Least Significant Difference) of the cost of 
psychotropic agents based on diagnosis 
(I) diagnosis (J) diagnosis 
Mean Difference 
(I-J) p-value 
95% Confidence 
Interval 
schizophrenia 
affective 
disorder 0.630 0.005* 0.193 1.067 
 Miscellaneous 1.593 0.000* 1.170 2.016 
affective 
disorder Schizophrenia -0.630 0.005* -1.067 -0.193 
  Miscellaneous 0.964 0.000* 0.501 1.426 
miscellaneous Schizophrenia -1.593 0.000* -2.016 -1.170 
  
affective 
disorder -0.964 0.000* -1.426 -0.501 
*Mean difference is significant at .05 ...  
(I) 
LOS 
(J) 
LOS 
Mean Difference 
(I-J) p-value 95% Confidence Interval 
1-5 6-10 -0.901 0.000* -1.369 -0.434 
 >10 -2.164 0.000* -2.557 -1.770 
6-10 1-5 0.901 0.000* 0.433 1.369 
  >10 -1.262 0.000* -1.649 -0.876 
>10 1-5 2.164 0.000* 1.770 2.557 
  6-10 1.262 0.000* 0.876 1.649 
*Mean difference is significant at .05 ... 
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4.7.4 Relationship between the mean cost of all drugs and patients’ 
characteristics 
 
In terms of the mean cost of all drugs, the mean cost of male patients 
($191.99±251.40) was statistically significantly higher than female patients 
($117.96±147.87).  The one-way analysis of the cost of all drugs found statistically 
significant differences in mean costs for patients in the different length of stay 
groups and by diagnosis (Table 4.25).  
 
Table 4.25 Analysis of the mean cost of all drugs 
Independent variables T F p-value 
Gender -2.558  0.011 
Psychiatrist team 0.939  0.349 
Age (years)  0.823 0.441 
Length of stay (days)  64.765 0.000 
Diagnosis  27.999 0.000 
Antipsychotic use pattern  1.995 0.097 
 
 
The results of the LSD tests indicated highly statistically significant differences 
(p<0.001) in mean costs based on the three groups of patient length of stay (Table 
4.26). The mean cost of all drugs for patients who stayed in hospital more than 10 
days ($251.79±257.32) was significantly higher than for the two other LOS 
categories ($26.41±21.40 and $72.51±60.70 for 1 to 5 days and 6 to 10 days 
respectively) and for patients who stayed in hospital between 6 and 10 days was 
statistically significantly higher those with a length of stay of 5 or less days. 
 
Table 4.26 Post hoc test (Least Significant Difference) of the cost of all drugs 
based on patients’ length of stay 
(I) 
LOS 
(J) 
LOS 
Mean Difference 
(I-J) p-value 
95% Confidence 
Interval 
1-5 6-10 -0.948 0.000* -1.404 -0.493 
 >10 -2.122 0.000* -2.506 -1.739 
6-10 1-5 0.948 0.000* 0.493 1.404 
  >10 -1.174 0.000* -1.551 -0.797 
>10 1-5 2.122 0.000* 1.739 2.506 
  6-10 1.174 0.000* 0.797 1.551 
*Mean difference is significant at .05 ... 
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The mean cost of all drug used by schizophrenic patients ($232.92±241.78) was 
statistically significantly higher than for other groups ($181.14±253.06 for affective 
disorders and $56.35±63.22 for other diagnoses) and for affective disorders was 
statistically significantly higher than for patients in the miscellaneous diagnosis 
category (Table 4.27).  
 
Table 4.27 Post hoc test (Least Significant Difference) of the cost of all drugs 
based on diagnosis 
(I) diagnosis (J) diagnosis 
Mean Difference 
(I-J) p-value 
95% Confidence 
Interval 
schizophrenia 
affective 
disorder 0.562 0.010* 0.137 0.987 
 miscellaneous 1.555 0.000* 1.144 1.966 
Affective 
disorder schizophrenia -0.562 0.010* -0.987 -0.137 
  miscellaneous 0.993 0.000* 0.543 1.443 
miscellaneous schizophrenia -1.555 0.000* -1.966 -1.144 
  
affective 
disorder -0.993 0.000* -1.443 -0.543 
*Mean difference is significant at .05 ... 
 
 
4.7.5 Relationship between the mean total costs and patients’ 
characteristics 
 
The one-way analysis of variance exploring differences in total costs showed that 
the significant differences in mean total cost were between patients in different age 
groups (F=3.500, p=0.032), in the different length of stay groups (F=284.353, 
P<0.001), and in different diagnosis group (F=25.356, p<0.001) (Table 4.28). 
 
Table 4.28 Analysis of the mean of total treatment costs 
Independent variables T F p-value 
Gender -1.431  0.182 
Psychiatrist team 1.946  0.053 
Age (years)  3.500 0.032 
Length of stay (days)  284.353 0.000 
Diagnosis  25.356 0.000 
Antipsychotic use pattern  0.523 0.719 
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The patients aged less than 35 years ($5,939.24±6,427.29) had a statistically lower 
mean total cost than patients in other age groups while patients in the 35-44 year 
group ($8,075.80±8,014.92) had a significantly higher mean total cost that those in 
the 35 years and less age group. The LSD test also indicated the mean total cost of 
the 35-44 year group was not significantly different from the mean total cost of 
patients aged more than 44 years ($7,238.94± 6,072.16) (Table 4.29).  
 
Table 4.29 Post hoc test (Least Significant Difference) of the total cost based 
on age 
(I) age (J) age 
Mean Difference 
(I-J) p-value 
95% Confidence 
Interval 
<35 35-44 -0.390 0.020* -0.718 -0.061 
 >44 -0.366 0.047* -0.726 -0.006 
35-44 <35 0.390 0.020* 0.061 0.718 
 >44 0.024 0.903 -0.365 0.413 
>44 <35 0.366 0.047* 0.006 0.726 
 35-44 -0.024 0.903 -0.413 0.365 
*Mean difference is significant at .05 ... 
 
 
The LSD tests showed highly statistically significant differences (p<0.001) in mean 
costs based on the three groups of patient length of stay (Table 4.30). The total mean 
cost of patients with a LOS of more than 10 days ($10,594.14±$7,288.83) was 
statistically significantly higher than for other groups ($3,119.81±$537.01 for the 6 
to 10 days group and $1,196.47±$499.61 for 6 days group) meanwhile for patients 
who stayed in hospital between 6 and 10 days was statistically significantly higher 
those with a length of stay of 5 or less days. 
 
Table 4.30 Post hoc test (Least Significant Difference) of the total cost based 
on patients’ length of stay 
(I) LOS (J) LOS 
Mean Difference 
(I-J) p-value 
95% Confidence 
Interval 
1-5 6-10 -1.040 0.000* -1.253 -0.828 
 >10 -2.101 0.000* -2.280 -1.922 
6-10 1-5 1.040 0.000* 0.828 1.253 
  >10 -1.061 0.000* -1.237 -0.885 
>10 1-5 2.101 0.000* 1.922 2.280 
  6-10 1.061 0.000* 0.885 1.237 
*Mean difference is significant at .05 ...   
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The LSD tests of total cost based on diagnosis indicated the mean total cost for 
schizophrenia patients ($9,169.50±7,301.52) was statistically significantly higher 
than for patients with affective disorder ($7,506.30±7,866.85) and patients in the 
miscellaneous group ($3,400.21±3,131.54), and for patients with affective disorders 
was statistically significantly higher than for patients in the miscellaneous diagnosis 
category.  (Table 4.31).  
 
Table 4.31 Post hoc test (Least Significant Difference) of the total cost based 
on diagnosis 
(I) diagnosis (J) diagnosis 
Mean Difference 
(I-J) p-value 
95% Confidence 
Interval 
schizoprenia 
Affective 
disorder 0.361 0.024* 0.049 0.673 
 Miscellaneous 1.084 0.000* 0.782 1.386 
Affective 
disorder Schizophrenia -0.361 0.024* -0.673 -0.049 
  Miscellaneous 0.723 0.000* 0.383 1.054 
miscellaneous Schizophrenia -1.084 0.000* -1.386 -0.782 
  
Affective 
disorder -0.723 0.000* -1.054 -0.393 
*Mean difference is significant at .05 ... 
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5 Discussion 
 
This study has examined the demographic and clinical characteristics of a cohort of 
psychiatric inpatients who were prescribed antipsychotic agents, their treatment 
patterns, and the cost of treatment. 
 
Of psychiatric inpatients at this hospital, 70% were on antipsychotic medication. 
This finding was lower than reported in the studies by Paton et al 
98
, Bowers et al
57
 
and Mauri
1
 (around 85%) but higher than the finding of  the study by Botvinik et al 
(59%).
99
 This use of antipsychotic medications was not surprising given the high 
proportion of patients with schizophrenia as the common indication of antipsychotic 
agents is treating psychotic symptom (amelioration of delusion and hallucination).
21, 
38, 99
  
 
5.1 Patient demographics  
 
In this study the number of male patients (61%) was higher than the number of 
females (39%). This finding is consistent with the results of Botvinik’s study99 
(64%) and slightly higher than Paton (59%)
98
 and Bowers (58.2%)
57
 studies.  In 
contrast, Mauri et al
1
 in their study conducted in 1999 and 2002 found the proportion 
of male patients was less than 50%.  
 
The mean age of patients in current study (35.87±11.11 years) was younger than 
some previous studies,
1, 57
 but consistent with the findings of a survey conducted by 
the Australian Bureau of Statistics in 2004-2005,
100
 in which the prevalence of 
mental problems generally increased with age until the 35 t0 44 year age group and 
declined over this group.  
 
Differences found in the age distribution of males and females could possibly be 
explained by differences in the onset and prevalence of disorders among females and 
males.
3, 33
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5.2 Clinical characteristics 
 
The mean LOS in this study (18.0 ± 18.3 days) was shorter than that in the Bolvenik 
study (23.5 ± 21.9 days),
99
 but similar to that reported in the Mauri study (16.36 ± 
18.45 days).
1
 The majority of patients in the current study were hospitalized for no 
more than 10 days. This relatively short LOS could be because  most patients were 
treated with atypical drugs, as the first line treatment option for psychosis.
3
  
 
In the current study, most patients were diagnosed with schizophrenia (40.7%), 
followed by affective disorder (bipolar disorder and depression), drug induced 
psychosis and personality disorder. A similar distribution of diagnoses among 
patients was found by Paton et al.
98
  
 
The high proportion of patients with schizophrenia was not surprising because the 
common indication of antipsychotic agents is treating psychotic symptoms 
(amelioration of delusion and hallucination).
99
 Because of its other indications, such 
as augmentation of antidepressants, relief of anxiety symptom and lessening of 
agitation (sedation), and control of behaviors (including self-harm and aggression) 
associated with personality disorders and mood stabilization, antipsychotic agents 
are also used in treating other disorders.
99
 
 
5.3 Relationship between demographics and clinical 
characteristics 
 
The relative number of women and men in each length of stay category was similar, 
which may reflect a similar level of severity of illness in both groups even though 
they had different patterns of diagnoses. 
 
Although the length of stay of patients in different age groups was not statistically 
significantly different, older patients had a slightly longer hospital stay than younger 
patients. This could be because the onset of mental disorders is usually in the late 
teens through until around the 40s.
33
 As a result, the severity of illness in older 
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patient is usually more severe than that in younger patients. In addition, younger 
patient are usually more tolerant to treatment with psychiatric drugs.  
 
In this current study, the pattern of length of hospitalization of patient with each 
diagnosis was similar to the pattern found in the Davids study
45
, in which patients 
with schizophrenia and affective disorder were treated longer than other patients. As 
one of the most disabling disorders,
3
 it is not surprising that patients with 
schizophrenia had the longest time of length of hospitalization. 
 
However, the duration of admission in this study was significantly shorter than those 
in Davids’ previous study.45 Patients with schizophrenia and affective disorders in 
the current study were treated for around 20 days but in Davids’ study the patients 
stayed in hospital about 40 to 50 days. 
45
 In the case of patients with personality 
disorders and mental disorder due to psychoactive substance, in this study these 
patients were hospitalized for approximately eight days and ten days, respectively, 
while in Davids’ the equivalent hospital episodes were around 29 and 13 days, 
respectively. The shorter length o stay in this study could be because the use of 
atypical drugs, which is associated with decreased psychiatric hospitalization rate, 
shortened length of stay per episode and fewer hospital days per year.
86
 In current 
study 154 of 182 inpatients (84.6%) used atypical drugs while in the Davids patients 
fewer than 30% of the study patients used atypicals. In addition, data from the three 
reference years (1998, 2001 and 2003) in the Davids study showed increasing use of 
atypical antipsychotics for all diagnoses, which was concomitant with a decreasing 
length of stay.
45
  
 
Severity of illness,
101, 102
 treatment resistance,
103
 diagnosis, 
102, 104, 105
 and gender
102, 
104, 105
 are factors that generally determine the duration of hospitalization. 
Schizophrenic patients or patients with affective disorders who are chronically ill 
and resistant to treatment usually need long treatment in hospital while drug induced 
psychosis wears off even without treatment after the illicit drugs had gone out of the 
patients’ body. The atypical agents usually help to reduce psychosis and hence 
shorten the length of stay.  
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Psychiatrist team A and team B treated almost equal number of psychiatric patients 
in 2005. The length of stay of patients who were treated by each team were not 
statistically significantly different although the mean of stay of patients treated by 
team A was longer than that by team B (21.06 ± 21.20 days versus 14.08 ±. 12.93 
days). This may be explained by team A treating more schizophrenia patients (48%) 
than team B (31.3%). Schizophrenia patients had the longest mean length of stay of 
all compared with patients with  other diagnoses.
104
  
 
In this study, the percentage of males and females who suffered each psychiatric 
disorder was statistically significantly different. While the incidence of 
schizophrenia and bipolar disorder is generally similar in both genders,
3, 21, 33
 in this 
study, relatively fewer females were diagnosed with schizophrenia and bipolar 
disorders. The higher percentage of male inpatients suffering schizophrenia may be 
because of an earlier onset of this condition in men than women and women tend to 
have a better prognosis, a more benign course of illness, fewer hospital admissions 
and a better social functioning than men.
3, 21, 33
  
 
In this study, drug induced psychosis was diagnosed relatively more in male than 
female patients, which is consistent with the incidence of this disorder with the 
difference found to be more marked for non-alcohol substance than alcohol. 
33
 
 
More patients in the personality disorder category suffered borderline personality 
disorder, followed with patient with antisocial disorder. Borderline personality 
disorder is twice as common in women as in men, while antisocial is more common 
in men than in women.
33
 
 
Relatively more female patients were diagnosed with depression than males. This 
finding is similar with general population prevalence, with a twofold greater 
prevalence of depressive disorder in women than men.
33
 The reasons for the 
difference have been hypothesized to involve hormonal differences, the effect of 
childbirth, differing psychosocial stressors for women and men, and behavioral 
models of learned helplessness.
33
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The patterns of patients’ age across each diagnosis in this study were similar to a 
previous study.
45
 Patients with affective disorder were the oldest and patients with 
drug induced psychosis were the youngest. One of reason for the latter is that the 
highest rate of abuse and dependence on substance is found among people in their 
late teen to early twenties with rates of use lower in older age groups.
33
 Although 
these two studies had the same pattern of age by diagnosis, this study had a younger 
cohort of patients overall. In Davids study,
45
 the mean age of patients with 
schizophrenia was around 43 years, affective disorder was 52 years, personality 
disorder was 35 years and 41 years was the mean age of people with neurotic, stress 
related and somatoform disorder. In this current study the age of patients with 
schizophrenia, effective disorders, drug induced psychosis and other diagnoses were 
34, 41, 29 and 35 years old respectively.  
 
5.4 Patterns of antipsychotic and other psychotropic 
medications  
5.4.1 Medications as regular use 
 
Psychotropic drugs regularly prescribed for psychoses in this study were similar 
with a previous study.
62
 The most frequently prescribed were antipsychotics (mainly 
atypicals), followed by benzodiazepines, mood stabilizers, antidepressants and 
anticholinergics. 
 
In this current study, the use of atypical antipsychotic medications (32.6%) was 
more than ten fold that of typical drugs (2.9%). Of 182 cases, 106 cases (58.2%) 
were treated with one atypical and only nine cases (4.9%) with one typical. Most 
patients were treated with a single atypical antipsychotic, which is the correct 
prescribing policy of this hospital. In addition, atypicals are as effective as the 
typicals in treatment of psychoses, but better tolerated because less likely to cause 
extrapyramidal side effects and also more efficacious for the negative symptoms and 
cognitive deficit.
3
 Antipsychotics, which have a major effect on the reduction of 
psychotic symptoms, are effective for treating schizophrenia and also other 
psychiatric disorders namely bipolar disorder, depression with psychotic features, 
personality disorder, and substance-induced psychotic disorder.
1, 21, 33, 38, 57
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Combination atypical medications were also commonly prescribed for patients in 
this study, with 53 cases (29.1%) treated with these combinations. In contrast, only 
two cases (1.1%) were treated with combination typicals. Polytherapy by using 
typicals with atypical medication was quite often, accounting for 32 cases (17.6%). 
This finding differed from the finding in Paton’s study,71 which reported typical 
antipsychotics accounting for 51.6% of routine prescriptions. Other studies have 
shown that polypharmacy is common among patients with severe mental illness.
11, 
83, 106 
  The results of these studies were similar to the current study in which 
antipsychotic polytherapy was common among males, patients less than 30 years old 
and schizophrenic patients.
11, 106
 Although the majority of experts suggest 
monotherapy, polypharmacy is considered to be essential in specific cases such as 
treatment for high levels of agitation and danger to the patient himself or others, 
therapy resistance, non responsiveness to monotherapy, and avoidance of adverse 
events from high dosing of a single agent.
 11, 46, 106
 
 
Olanzapine was the most often prescribed as monotherapy and polytherapy with 
other antipsychotics. This finding is consistent with some previous studies
57, 98
 but 
one other study reported that risperidone was used most commonly followed by 
haloperidol and olanzapine.
1
 Both findings adhere with a consensus
3, 86, 1073, 86, 1073, 86, 
107
  that the newer antipsychotic medications, namely olanzapine, risperidone and 
quetiapine, should be the first-line treatment option for first episode and relapse of 
schizophrenia.
 2, 59, 82
 Quatiapine and risperidone were the second and third most 
often used in this current study, however the Paton’s study reported clozapine and 
risperidone were the second and third, and quetiapine was the fifth atypical that most 
commonly used.
98
  
 
The typical antipsychotic medication that was most commonly prescribed in this 
current study was chlorpromazine. This finding is similar with a previous study
98
 
that also found chlorpromazine was the most frequently used. Beside used as 
monotherapy, chlorpromazine also was frequently prescribed concurrently with 
other typical and atypical antipsychotics. Again this finding is similar with a 
previous study.
99
 This use of chlorpromazine results from it being used as the 
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sedative agent of choice since it causes marked sedation and moderate 
extrapyramidal effects.
3
  
 
Combination olanzapine with quetiapine and olanzapine with risperidone were the 
most common atypical polytherapy in this study. This finding was similar with the 
result of a study conducted by Centorrino et al.
67
 However, in this latter study, a 
combination of olanzapine with haloperidol was the most frequently occurring 
combination,
67
 while in the current study, olanzapine with chlorpromazine was the 
most frequently occurring. 
 
Beside antipsychotics, other psychotropic medications, such as anxiolytic and 
hypnotic, antidepressants, mood stabilizers and anticholinergic medications were 
used for treating psychiatric patients. These drugs are used to diminish symptoms. 
Anxiolytics and hypnotic therapy treat anxiety, agitation and insomnia and its short-
term use can be particularly useful in acute episodes.
3
 Antidepressants are used 
when a depressive component of mental disorder is present.
3
 Mood stabilizers are 
for treatment of mania.
3
 Anticholinergics are commonly used to diminish 
extrapyramidal effects caused by the conventional antipsychotics. 
3, 108
   
5.4.2 Medications as PRN use 
 
The pattern of drug use was slightly changed when medications on a PRN basis 
were included in the data. Although the use of medications as required prescription 
medication contribute to polypharmacy, high doses, side effects and dangerous drug 
interaction, this practice is common in inpatient psychiatric treatment.
11, 62, 63, 65, 109, 
110
  
 
Antipsychotics, anxiolytics and hypnotics, and anticholinergic drugs were 
psychotropics that were commonly prescribed as PRN drugs. The results of this 
study are similar to those reported in previous studies.
59, 62, 108
  PRN antipsychotics, 
anxiolytics and hypnotics are usually used for managing acute psychosis in patient 
symptoms and behaviours while anticholinergics are for treating parkinsonian side 
effects. 
62-64, 110
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While the research of Simon et al.
108
 showed that non-psychotropics such as 
analgesics and drugs for gastrointestinal disorder were prescribed most commonly 
on a PRN basis, in this current research analgesics and salbutamol inhaler were most 
commonly prescribed. These medications treat the comorbidities. 
 
5.4.3 Association between prescribing pattern of antipsychotics 
and patients’ characteristics. 
 
The only statistically significant difference in the pattern of use of antipsychotics 
was between diagnosis, with the difference largely explained by differences between 
the patterns of antipsychotics used for treating schizophrenic patients and the other 
two groups of patients ( affective disorders group and miscellaneous group). Patients 
with schizophrenia were treated relatively more frequently with risperidone, 
combination atypicals and other monotherapy atypicals than patients with affective 
disorder and miscellaneous disorders. On the other hand, patients with affective 
disorder and other disorders were treated relatively more frequently with olanzapine 
and quetiapine. 
 
Further investigation indicated that the odd of schizophrenic patients being treated 
with risperidone rather than olanzapine was 4.348 times higher than for patients with 
other diagnoses (drug induced psychosis, personality disorder, miscellaneous group). 
The odds of schizophrenic patients being treated with combination atypicals rather 
than olanzapine was also 5.388 times higher than patient in other diagnoses.  
 
When PRN antipsychotic drug were included in the data, the patterns of treatment 
differed between diagnoses and also between psychiatrist teams. Combination 
atypicals were most frequently for patients diagnosed with schizophrenia while two 
other groups of diagnoses were most commonly prescribed olanzapine. 
Schizophrenic patients were 6.178 times more likely to be on combination atypicals 
rather than olanzapine when compared with patients with miscellaneous diagnoses. 
When the psychiatrist team B was compared with the team A, team B preferred to 
use olanzapine to miscellaneous antipsychotics (other monotherapy atypical, typical, 
combination atypical-typical) (odds=2.915).  
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Although clinicians usually use atypical antipsychotics such as risperidone and 
olanzapine as first-line treatment for psychotic episode,
3, 111
 the results discussed 
above cannot conclude that the effectiveness of  risperidone or combination 
atypicals is superior to olanzapine since the comparative effectiveness amongst 
atypicals is debatable. 
3, 111
 In addition, diagnosing psychiatric disorders diagnoses is 
complicated and sufficient information not always provided to determine appropriate 
drugs.
69
 For determining treatment for each patient, physicians should base their 
decisions on the clinical characteristics of the patient and drug properties.
3
  
 
5.5 Economic analysis 
 
The economic analysis of treatment costs showed that the mean of costs for treating 
male patients were higher than females, and these differences were statistically 
significant for the cost for antipsychotics, psychotropics, and all drugs. This may 
have resulted from the longer length of stay of male patients and the higher number 
of male patients suffering schizophrenia.  
 
Although the costs for antipsychotics, psychotropics, all drugs and total expenditure 
between psychiatrist team A and B were not statistically significant, the patients 
were treated by team A had higher costs than team B. This finding may also be a 
result of the relative higher number of schizophrenic patients treated by team A. 
 
The patients aged more than 44 years had the lowest mean costs of antipsychotics, 
psychotropics, and all drugs while the patients aged less than 35 years had the lowest 
mean total cost. The age group with the highest costs in all cost categories was the 
33 to 44 year old group in which almost half the patients suffered from 
schizophrenia and this group also had the highest length of stay. 
 
In terms of length of stay, the results indicated that the mean costs of patients 
admitted for one to five days were a tenth of the costs of patients who were 
hospitalized more than ten days and around a third of the costs of patients who were 
hospitalized 5 to 10 days.   
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The costs for treatment schizophrenic patients were the highest, followed by 
affective disorders and other diagnoses. A study in USA also found that psychosis 
diagnosis was associated with higher treatment costs. 
86
 
 
The above results show that length of stay and a schizophrenia diagnosis influence 
the costs. Longer stays in hospital automatically lead to increase in other costs such 
as drugs and laboratory tests.
79
 Since hospitalization is the greatest contributor to the 
direct costs,
10, 79, 80
  a reduction in hospital use would have an important impact on 
the overall costs of the illness.
81
 
 
Compared with other psychiatric disorders, schizophrenic patients usually use more 
inpatient facilities.
75, 86
 The study by Garattini et al also found that the cost 
associated with drug therapy and laboratory tests for patients with related psychotic 
disorder were  significantly higher than these costs for other patients.
75
 
 
The mean cost of antipsychotic medications for treating patients on olanzapine, 
quetiapine, risperidone, combination atypical and other antipsychotics (other 
atypical mono therapy, typicals, combination atypical-typical antipsychotics) were 
different significantly. While the mean costs of antipsychotics, psychotropics, and 
all drugs for patients on combination atypical were the highest,  risperidone had the 
highest of the total cost because of patients on this drug were hospitalized longer 
than others.  A previous study show different figures. 
86
  In this study, the highest 
total cost was for olanzapine users because this group had the highest inpatient use 
while the users of combination of atypicals had the lowest total cost.
86
 Although the 
cost of antipsychotic medications comprise a minor portion of the direct costs  of 
schizophrenia, they can have the major impact on costly aspects of care such as 
hospital admission.
10
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5.6 Study limitations and area of future research 
 
The limitations and recommendations for future research of this study were as 
follows- 
- It was a retrospective study using existing data that have been recorded for 
reasons other than research. The accuracy of the data therefore relied on 
accuracy of the written record. 
- This study examined a relatively small sample size and reflected the trends in 
a single psychiatric ward in Western Australia in 2005. For this reason, the 
findings may not be generalizable to treatment of all psychiatric inpatients 
who are prescribed antipsychotic agents.  
- Prescribing post discharge was not evaluated so that the findings cannot be 
extrapolated to treatment setting outside of the hospital. 
- This study did not collect data on characteristics of prescribing physicians, 
patient symptoms, symptom severity, outcome measures, secondary 
diagnoses, adverse effects,  medication post discharge, total daily doses and 
whether the patients were first or subsequent admissions to the unit. 
Future studies examining the use of antipsychotics in hospital inpatient 
settings should include these items in their data collection in order to allow a 
more detailed evaluation of differences in the pattern of antipsychotic use 
and corresponding costs. 
- This study did not address questions relating to the appropriateness of 
prescribing practices by making a comparison with recommended or 
standard therapy for use of psychotropic medications in National Therapeutic 
Guidelines for psychotropic prescribing (e.g. eTGs). Assessing 
appropriateness of therapy is important but the question of appropriateness 
was outside the scope of the study. In order to assess appropriateness, 
additional data would have been required including patient symptoms, 
severity of symptoms, secondary diagnoses, outcome measures and the like. 
It is recommended that future studies be conducted to address the question of 
the appropriateness of prescribing practices of antipsychotics for hospital 
inpatients.  
  80 
In this study, chi-squared analysis and multinomial logistic regression used to 
determine the differences between demographic and clinical features, and the 
patterns of clinical use of antipsychotic medications. This analysis identify 
the differences but they do not provide the ability to determine 
specifically where the difference is per se. Using more sophisticated 
statistical analysis are  recommended  for future research in this area where 
there are multiple variables. 
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6 Conclusion 
Through reviewing the medical records of psychiatric patients who were admitted to 
AKMH in 2005, this study found the number of male patients was higher than the 
number of females and their mean age of all patients was 35.87±11.11 years. More 
than half of the patients were admitted to hospital for more than 10 days with the 
mean length of stay of 18.0 ± 18.3 days. Patients treated by psychiatrist team A were 
hospitalized longer than those by team B and team A treated more schizophrenic 
patients than team B. The most common diagnosis was schizophrenia. This finding 
is not surprising as the main indication of antipsychotics is for treating psychosis. 
 
In this study the use of atypical antipsychotics as the first line treatment of psychosis 
was more than tenfold that of typical drugs. These findings confirmed the trend of 
the use of atypical and typical antipsychotic medications, in which there is an 
increasing trend of atypical use and decreasing trend of typical use. In addition to 
antipsychotic medications; anxiolytic, hypnotic and anticholinergic drugs were given 
as needed drugs. This is a common practice in hospital although this practice 
contributes to polypharmacy, high doses, side effects and dangerous drug 
interactions. 
 
Only diagnosis influenced the prescribing patters of antipsychotics. Patients with 
schizophrenia were treated relatively more commonly with risperidone and 
combination atypicals than patients with affective disorder and miscellaneous 
disorders. Meanwhile these latter disorders were treated relatively more frequently 
with olanzepine and quetiapine. 
With regards to costs, schizophrenic patients had the highest mean cost per patient, 
largely because of their longer length of stays. Patients with schizophrenia also had 
the highest mean cost for drugs, including both antipsychotics and psychotropic 
drugs.  
The findings of this thesis in relation to the prescribing patterns of antipsychotic and 
other medications to psychiatric patients, the corresponding costs, and factors 
influencing prescribing patterns enables a better understanding to be gained of the 
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profile of admitted psychiatric patients and their treatment. In a hospital 
environment with limited budgets, this information is useful for both psychiatrists 
and pharmacists in the future management of patients and in decisions relating to the 
allocation of the pharmacy budget.  
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Appendix 3 Research Publication 
 
This study was presented as poster presentations at: 
1.  Annual Conference of the Australasian Pharmaceutical Science Association 
(APSA) in Adelaide, Australia, 3-5 December 2006 
 
 
THE PATTERNS OF USE OF ANTIPSYCHOTIC MEDICATIONS IN 
TREATING HOSPITALIZED PSYCHIATRIC PATIENTS 
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Background: Prescribing patterns of antipsychotic medications have changed over 
time. Underlying the increasing use of antipsychotics is the dramatic increase in the 
prescribing of atypical antipsychotics, with the use of typicals decreasing. Aim: The 
aim of this study was to evaluate the use of antipsychotics in treating hospitalized 
psychiatric patients at the Adult Psychiatry In-patient Unit, Armadale Kelmscott 
Memorial Hospital in 2005. Method: The medical records of hospitalized 
psychiatric patients who were treated with antipsychotic medications in 2005 were 
reviewed retrospectively. Data relating to patients’ age, gender, diagnosis and 
medication use was retrieved from those records. The data was analyzed to 
determine patterns of clinical use of antipsychotic medications. Results: Amongs 
hospitalized psychiatric patients who were being treated with antipsychotic 
medications in 2005, atypical antipsychotics as monotherapy were the most 
frequently prescribed (67.6%). Combinations of two or more atypicals were 
prescribed for 23.1% of patients while 4.4% of patients were on typical 
antipsychotics and 4.9% was being treated with combination typical-typical 
antipsychotics. Conclusion: The results of this study confirmed the trend of use of 
atypical and typical antipsychotics.  
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2. 5th Conference of Asian Association oof School of Pharmacy (AASP), in 
Bandung, Indonesiaa, 16-9 June 2011 
 
 
PRO RE NATA PRESCRIBING IN PSYCHIATRIC INPATIENTS 
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, Surabaya, Indonesia, 
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3
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Background: The use of pro re nata (PRN) medications has been common in 
psychiatric inpatient care for many years. This practice allows drugs to be 
administered on patient request or at nurses’ discretion for psychiatric symptoms, 
treatment side effects or physical complaints. Purposes: To determine the 
prevalence of PRN drug prescribing for inpatients at the Adult Psychiatry In-patient 
Unit, Armadale Kelmscott Memorial Hospital, Western Australia. Methods: The 
medical records of hospitalized psychiatric patients who are treated with 
antipsychotic medication were reviewed retrospectively. Data relating to medication 
use was retrieved from those records. The data was analyzed to determine the 
prevalence of PRN medications. Results: In this study, psychotropics were given as 
PRN drugs were antipsychotic, anxiolytic and hypnotic and anticholinergic 
medications. Atypical antipsychotic agents most commonly prescribed as PRN use 
were olanzepine (12 cases) and quetiapine (12 cases). In the typical group, 
chlorpromazine was the most frequently prescribed drug for PRN use, with it being 
used for 21 cases. Four patients also were treated with droperidol in PRN use. The 
numbers of patients receiving anxiolytic and hypnotic drugs as PRN prescription 
were extremely high. The number of patients getting lorazepam (58 patients) and 
clonazepam (44 patients) as PRN medications was approximately twice the number 
cases using these drugs as routine prescriptions (33 and 22 patients, respectively). 
The number of patients treated regularly with temazepam was similar with those 
with PRN use (around 40 patients). The use of anticholinergic medication as PRN 
medication was also high, with 19 patients in this category. Non anti psychotropic 
drugs that were used as PRN drugs in this study were analgesics, such as 
paracetamol, panadeine and ibuprofen and salbutamol sulphate inhaler. There were 
13 patient treated with paracetamol as needed drug, eight patients with panadeine, 
one patient with ibuprofen and 10 patients with salbutamol sulphate inhaler. 
Conclusion: The results of this study confirmed the trend of PRN drug prescribing 
in psychiatric patients. This is a common practice in hospital although this practice 
contributes to polypharmacy, high doses, side effects and dangerous drug interaction 
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